Cytokine	O
production	O
by	O
Vgamma	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
-T-cell	I-cell_type
subsets	I-cell_type
is	O
an	O
important	O
factor	O
determining	O
CD4	O
(	O
+	O
)	O
-Th-cell	O
phenotype	O
and	O
susceptibility	O
of	O
BALB/c	O
mice	O
to	O
coxsackievirus	O
B3-induced	O
myocarditis	O
.	O

Two	O
coxsackievirus	O
B3	O
(	O
CVB3	O
)	O
variants	O
(	O
H3	O
and	O
H310A1	O
)	O
differ	O
by	O
a	O
single	O
amino	O
acid	O
mutation	O
in	O
the	O
VP2	B-protein
capsid	I-protein
protein	I-protein
.	O

H3	O
induces	O
severe	O
myocarditis	O
in	O
BALB/c	O
mice	O
,	O
but	O
H310A1	O
is	O
amyocarditic	O
.	O

Infection	O
with	O
H3	O
,	O
but	O
not	O
H310A1	O
,	O
preferentially	O
activates	O
Vgamma4	B-cell_type
Vdelta4	I-cell_type
cells	I-cell_type
,	O
which	O
are	O
strongly	O
positive	O
for	O
gamma	B-protein
interferon	I-protein
(	O
IFN-gamma	B-protein
)	O
,	O
whereas	O
Vgamma1	B-cell_type
Vdelta4	I-cell_type
cells	I-cell_type
are	O
increased	O
in	O
both	O
H3	O
and	O
H310A1	O
virus-infected	O
animals	O
.	O

Depletion	O
of	O
Vgamma1	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
using	O
monoclonal	B-protein
anti-Vgamma1	I-protein
antibody	I-protein
enhanced	O
myocarditis	O
and	O
CD4	O
(	O
+	O
)	O
-	O
,	O
IFN-gamma	B-protein
(	O
+	O
)	O
-cell	O
responses	O
in	O
both	O
H3-	O
and	O
H310A1-infected	O
mice	O
yet	O
decreased	O
the	O
CD4	O
(	O
+	O
)	O
-	O
,	O
IL-4	O
(	O
+	O
)	O
-cell	O
response	O
.	O

Depleting	O
Vgamma4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
suppressed	O
myocarditis	O
and	O
reduced	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
IFN-gamma	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
but	O
increased	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
IL-4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
role	O
of	O
cytokine	O
production	O
by	O
Vgamma1	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
and	I-cell_type
Vgamma4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
investigated	O
by	O
adoptively	O
transferring	O
these	O
cells	O
isolated	O
from	O
H3-infected	O
BALB/c	O
Stat4	O
knockout	O
(	O
Stat4ko	O
)	O
(	O
defective	O
in	O
IFN-gamma	B-protein
expression	O
)	O
or	O
BALB/c	O
Stat6ko	O
(	O
defective	O
in	O
IL-4	O
expression	O
)	O
mice	O
into	O
H3	O
virus-infected	O
wild-type	O
BALB/c	O
recipients	O
.	O

Vgamma4	B-cell_type
and	I-cell_type
Vgamma1	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
T	I-cell_type
cells	I-cell_type
from	O
Stat4ko	O
mice	O
expressed	O
IL-4	B-protein
but	O
no	O
or	O
minimal	O
IFN-gamma	B-protein
,	O
whereas	O
these	O
cell	O
populations	O
derived	O
from	O
Stat6ko	O
mice	O
expressed	O
IFN-gamma	B-protein
but	O
no	O
IL-4	B-protein
.	O

Stat4ko	B-cell_type
Vgamma1	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
(	I-cell_type
IL-4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
)	O
suppress	O
myocarditis	O
.	O

Stat6ko	B-cell_type
Vgamma1	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
(	I-cell_type
IFN-gamma	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
)	I-cell_type
were	O
not	O
inhibitory	O
.	O

Stat6ko	B-cell_type
Vgamma4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
(	I-cell_type
IFN-gamma	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
)	I-cell_type
significantly	O
enhanced	O
myocarditis	O
.	O

Stat4ko	B-cell_type
Vgamma4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
cells	I-cell_type
(	I-cell_type
IL-4	I-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
)	I-cell_type
neither	O
inhibited	O
nor	O
enhanced	O
disease	O
.	O

These	O
results	O
show	O
that	O
distinct	O
gammadelta-T-cell	B-cell_type
subsets	I-cell_type
control	O
myocarditis	O
susceptibility	O
and	O
bias	O
the	O
CD4	B-cell_type
(	I-cell_type
+	I-cell_type
)	I-cell_type
-Th-cell	I-cell_type
response	O
.	O

The	O
cytokines	B-protein
produced	O
by	O
the	O
Vgamma	B-cell_type
subpopulation	I-cell_type
have	O
a	O
significant	O
influence	O
on	O
the	O
CD4	B-protein
(	O
+	O
)	O
-Th-cell	O
phenotype	O
.	O

JOURNAL	NULL
or	NULL
ViRoLOGY	NULL
,	NULL
July	NULL
2001	NULL
,	NULL
p.	NULL
5860-5869	NULL
0022-538	NULL
%	NULL
X/01/	NULL
$	NULL
04.00+0	NULL
-	NULL
DOI	NULL
:	NULL
10.1128/JV1.75.13.5860-5869.2001	NULL
Vol	NULL
.	NULL

75	NULL
,	NULL
No	NULL
.	NULL

13	NULL
Copyright	NULL
©	NULL
2001	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Cytokine	NULL
Production	NULL
by	NULL
Vy	NULL
*-T-Cell	NULL
Subsets	NULL
Is	NULL
an	NULL
Important	NULL
Factor	NULL
Determining	NULL
CD4	NULL
*-Th-Cell	NULL
Phenotype	NULL
and	NULL
Susceptibility	NULL
of	NULL
BALB/c	NULL
Mice	NULL
to	NULL
Coxsackievirus	NULL
B3-Induced	NULL
Myocarditis	NULL
SALLY	NULL
A.	NULL
HUBER	NULL
,	NULL
``	NULL
*	NULL
DANIELLE	NULL
GRAVELINE	NULL
,	NULL
'	NULL
WILLI	NULL
K.	NULL
BORN	NULL
,	NULL
``	NULL
anp	NULL
REBECCA	NULL
L.	NULL
O'BRIEN	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
University	NULL
of	NULL
Vermont	NULL
,	NULL
Burlington	NULL
,	NULL
Vermont	NULL
,	NULL
``	NULL
and	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
National	NULL
Jewish	NULL
Medical	NULL
and	NULL
Research	NULL
Center	NULL
,	NULL
Denver	NULL
,	NULL
Colorado®	NULL
Received	NULL
24	NULL
January	NULL
2001/Accepted	NULL
3	NULL
April	NULL
2001	NULL
Two	NULL
coxsackievirus	NULL
B3	NULL
(	NULL
CVB3	NULL
)	NULL
variants	NULL
(	NULL
H3	NULL
and	NULL
H310A1	NULL
)	NULL
differ	NULL
by	NULL
a	NULL
single	NULL
amino	NULL
acid	NULL
mutation	NULL
in	NULL
the	NULL
VP2	NULL
capsid	NULL
protein	NULL
.	NULL

H3	NULL
induces	NULL
severe	NULL
myocarditis	NULL
in	NULL
BALB/c	NULL
mice	NULL
,	NULL
but	NULL
H310A1	NULL
is	NULL
amyocarditic	NULL
.	NULL

Infection	NULL
with	NULL
H3	NULL
,	NULL
but	NULL
not	NULL
H310A1	NULL
,	NULL
preferentially	NULL
activates	NULL
Vy4	NULL
V64	NULL
cells	NULL
,	NULL
which	NULL
are	NULL
strongly	NULL
positive	NULL
for	NULL
gamma	NULL
interferon	NULL
(	NULL
IFN-y	NULL
)	NULL
,	NULL
whereas	NULL
Vy1	NULL
V684	NULL
cells	NULL
are	NULL
increased	NULL
in	NULL
both	NULL
H3	NULL
and	NULL
H310A1	NULL
virus-infected	NULL
animals	NULL
.	NULL

Depletion	NULL
of	NULL
Vy1*	NULL
cells	NULL
using	NULL
monoclonal	NULL
anti-Vy1	NULL
antibody	NULL
enhanced	NULL
myocarditis	NULL
and	NULL
CD4	NULL
*-	NULL
,	NULL
IFN-y	NULL
*-cell	NULL
responses	NULL
in	NULL
both	NULL
H3-	NULL
and	NULL
H310A1-infected	NULL
mice	NULL
yet	NULL
decreased	NULL
the	NULL
CD4	NULL
*-	NULL
,	NULL
IL-4*-cell	NULL
response	NULL
.	NULL

Depleting	NULL
Vy4*	NULL
cells	NULL
suppressed	NULL
myocarditis	NULL
and	NULL
reduced	NULL
CD4*	NULL
IFN-y*	NULL
cells	NULL
but	NULL
increased	NULL
CD4*	NULL
IL-4*	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
role	NULL
of	NULL
cytokine	NULL
production	NULL
by	NULL
Vy1*	NULL
and	NULL
Vy4~*	NULL
T	NULL
cells	NULL
was	NULL
investigated	NULL
by	NULL
adoptively	NULL
transferring	NULL
these	NULL
cells	NULL
isolated	NULL
from	NULL
H3-infected	NULL
BALB/c	NULL
Stat4	NULL
knockout	NULL
(	NULL
Stat4ko	NULL
)	NULL
(	NULL
defective	NULL
in	NULL
IFN-y	NULL
expression	NULL
)	NULL
or	NULL
BALB/c	NULL
Statéko	NULL
(	NULL
defective	NULL
in	NULL
IL-4	NULL
expression	NULL
)	NULL
mice	NULL
into	NULL
H3	NULL
virus-infected	NULL
wild-type	NULL
BALB/c	NULL
recipients	NULL
.	NULL

Vy4	NULL
and	NULL
Vy1*	NULL
T	NULL
cells	NULL
from	NULL
Stat4ko	NULL
mice	NULL
expressed	NULL
IL-4	NULL
but	NULL
no	NULL
or	NULL
minimal	NULL
IFN-y	NULL
,	NULL
whereas	NULL
these	NULL
cell	NULL
populations	NULL
derived	NULL
from	NULL
Statéko	NULL
mice	NULL
expressed	NULL
IFN-y	NULL
but	NULL
no	NULL
IL-4	NULL
.	NULL

Stat4ko	NULL
Vy1~*	NULL
cells	NULL
(	NULL
IL-4*	NULL
)	NULL
suppress	NULL
myocarditis	NULL
.	NULL

Statéko	NULL
Vy1*	NULL
cells	NULL
(	NULL
IFN-y	NULL
*	NULL
)	NULL
were	NULL
not	NULL
inhibitory	NULL
.	NULL

Statéko	NULL
Vy4~*	NULL
cells	NULL
(	NULL
IFN-y	NULL
*	NULL
)	NULL
significantly	NULL
enhanced	NULL
myocarditis	NULL
.	NULL

Stat4ko	NULL
Vy4*	NULL
cells	NULL
(	NULL
IL-4~*	NULL
)	NULL
neither	NULL
inhibited	NULL
nor	NULL
enhanced	NULL
disease	NULL
.	NULL

These	NULL
results	NULL
show	NULL
that	NULL
distinct	NULL
y8-T-cell	NULL
subsets	NULL
control	NULL
myocarditis	NULL
susceptibility	NULL
and	NULL
bias	NULL
the	NULL
CD4*-Th-cell	NULL
response	NULL
.	NULL

The	NULL
cytokines	NULL
produced	NULL
by	NULL
the	NULL
Vy	NULL
subpopu-	NULL
lation	NULL
have	NULL
a	NULL
significant	NULL
influence	NULL
on	NULL
the	NULL
CD4	NULL
*-Th-cell	NULL
phenotype	NULL
.	NULL

T	NULL
cells	NULL
expressing	NULL
the	NULL
y8	NULL
T-cell	NULL
receptor	NULL
(	NULL
TcR	NULL
)	NULL
accumulate	NULL
at	NULL
inflammatory	NULL
sites	NULL
and	NULL
can	NULL
modulate	NULL
disease	NULL
susceptibility	NULL
by	NULL
either	NULL
promoting	NULL
or	NULL
suppressing	NULL
inflammation	NULL
(	NULL
4	NULL
,	NULL
6	NULL
,	NULL
9	NULL
,	NULL
13	NULL
,	NULL
17	NULL
,	NULL
20	NULL
,	NULL
27	NULL
,	NULL
28	NULL
,	NULL
35	NULL
,	NULL
36	NULL
,	NULL
38	NULL
,	NULL
41	NULL
,	NULL
44	NULL
)	NULL
.	NULL

In	NULL
some	NULL
models	NULL
,	NULL
y8	NULL
*	NULL
T	NULL
cells	NULL
have	NULL
both	NULL
pro-	NULL
and	NULL
anti-inflammatory	NULL
effects	NULL
at	NULL
different	NULL
times	NULL
in	NULL
the	NULL
disease	NULL
process	NULL
.	NULL

In	NULL
the	NULL
models	NULL
of	NULL
arthritis	NULL
and	NULL
spontaneous	NULL
abortion	NULL
,	NULL
the	NULL
y8	NULL
*	NULL
T	NULL
cells	NULL
that	NULL
were	NULL
present	NULL
early	NULL
in	NULL
the	NULL
disease	NULL
in	NULL
both	NULL
models	NULL
were	NULL
proinflammatory	NULL
and	NULL
led	NULL
to	NULL
abortion	NULL
while	NULL
those	NULL
that	NULL
were	NULL
present	NULL
later	NULL
were	NULL
anti-inflammatory	NULL
and	NULL
inhibited	NULL
abortion	NULL
(	NULL
5	NULL
,	NULL
36	NULL
)	NULL
.	NULL

The	NULL
biological	NULL
effect	NULL
of	NULL
y8	NULL
¢	NULL
T	NULL
cells	NULL
may	NULL
be	NULL
mediated	NULL
by	NULL
the	NULL
cytokines	NULL
they	NULL
produce	NULL
.	NULL

y8¢	NULL
T	NULL
cells	NULL
can	NULL
produce	NULL
cytokines	NULL
of	NULL
either	NULL
a	NULL
Th1	NULL
(	NULL
gamma	NULL
interferon	NULL
[	NULL
IFN-y	NULL
]	NULL
)	NULL
or	NULL
Th2	NULL
(	NULL
interleukin	NULL
4	NULL
[	NULL
IL-4	NULL
]	NULL
)	NULL
phenotype	NULL
,	NULL
and	NULL
which	NULL
phenotype	NULL
occurs	NULL
can	NULL
be	NULL
dependent	NULL
upon	NULL
the	NULL
type	NULL
of	NULL
antigen	NULL
used	NULL
for	NULL
their	NULL
activation	NULL
or	NULL
the	NULL
subtype	NULL
of	NULL
y8	NULL
``	NULL
T	NULL
cells	NULL
stimu-lated	NULL
.	NULL

y8	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
arthritis	NULL
(	NULL
4	NULL
)	NULL
and	NULL
in	NULL
murine	NULL
cytomegalovirus	NULL
and	NULL
Nippostrongylus	NULL
brasiliosis	NULL
infection	NULL
(	NULL
7	NULL
)	NULL
predominantly	NULL
make	NULL
IL-4	NULL
and	NULL
induce	NULL
Th2	NULL
differentiation	NULL
in	NULL
CD4	NULL
*	NULL
-T-cell	NULL
populations	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
Listeria	NULL
monocytogenes	NULL
,	NULL
Salmonella	NULL
choleraesuis	NULL
,	NULL
and	NULL
murine	NULL
cytomegalovirus	NULL
infections	NULL
,	NULL
y8	NULL
``	NULL
T	NULL
cells	NULL
produce	NULL
IFN-y	NULL
and	NULL
promote	NULL
CD4	NULL
*-Th1-cell	NULL
responses	NULL
(	NULL
7	NULL
,	NULL
30	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Studies	NULL
by	NULL
Azuara	NULL
and	NULL
Pereira	NULL
(	NULL
1	NULL
)	NULL
and	NULL
Gerber	NULL
and	NULL
colleagues	NULL
(	NULL
10	NULL
)	NULL
indicate	NULL
that	NULL
in	NULL
DBA/2	NULL
mice	NULL
y8*	NULL
T	NULL
lymphocytes	NULL
which	NULL
express	NULL
the	NULL
Vy1	NULL
V86.4	NULL
TeR	NULL
predominantly	NULL
express	NULL
IL-4	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
type	NULL
of	NULL
y8	NULL
``	NULL
cell	NULL
subset	NULL
activated	NULL
during	NULL
an	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
University	NULL
of	NULL
Vermont	NULL
,	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
208	NULL
S.	NULL
Park	NULL
Dr.	NULL
,	NULL
Suite	NULL
2	NULL
,	NULL
Colchester	NULL
,	NULL
VT	NULL
05446	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
802	NULL
)	NULL
656-8944	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
802	NULL
)	NULL
656-8965	NULL
.	NULL

E-mail	NULL
:	NULL
shuber	NULL
@	NULL
salus.med.uym.edu	NULL
.	NULL

5860	NULL
immune	NULL
response	NULL
may	NULL
be	NULL
crucial	NULL
to	NULL
its	NULL
modulatory	NULL
effect	NULL
on	NULL
CD4	NULL
*-T-cell	NULL
responses	NULL
.	NULL

Previous	NULL
studies	NULL
from	NULL
this	NULL
laboratory	NULL
demonstrated	NULL
that	NULL
y8	NULL
*	NULL
T	NULL
cells	NULL
control	NULL
susceptibility	NULL
of	NULL
mice	NULL
to	NULL
coxsackievirus	NULL
B3	NULL
(	NULL
CVB3	NULL
)	NULL
-induced	NULL
myocarditis	NULL
(	NULL
14	NULL
,	NULL
15	NULL
,	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Most	NULL
recently	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
Vy1	NULL
*	NULL
T	NULL
cells	NULL
cause	NULL
myocarditis	NULL
resistance	NULL
in	NULL
CVB3-infected	NULL
C57BL/6	NULL
mice	NULL
but	NULL
that	NULL
Vy4*	NULL
T	NULL
cells	NULL
activated	NULL
in	NULL
Bl.Tg.Ea	NULL
animals	NULL
,	NULL
i.e	NULL
.	NULL

,	NULL
C57BL/6	NULL
mice	NULL
transgenically	NULL
made	NULL
to	NULL
express	NULL
major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
II	NULL
IE	NULL
,	NULL
cause	NULL
myocarditis	NULL
susceptibility	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
major	NULL
problem	NULL
with	NULL
this	NULL
earlier	NULL
study	NULL
was	NULL
that	NULL
Vy4~*	NULL
cells	NULL
are	NULL
more	NULL
prevalent	NULL
in	NULL
uninfected	NULL
Bl.Tg.Ea	NULL
animals	NULL
whereas	NULL
Vy1	NULL
*	NULL
cells	NULL
predominate	NULL
in	NULL
C57BL/6	NULL
mice	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
was	NULL
possible	NULL
that	NULL
CVB3	NULL
infection	NULL
was	NULL
simply	NULL
activating	NULL
the	NULL
dominant	NULL
y8	NULL
*-T-cell	NULL
population	NULL
in	NULL
the	NULL
two	NULL
strains	NULL
rather	NULL
than	NULL
selectively	NULL
activating	NULL
either	NULL
population	NULL
specifically	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
begin	NULL
with	NULL
the	NULL
same	NULL
mouse	NULL
strain	NULL
,	NULL
BALB/c	NULL
,	NULL
and	NULL
show	NULL
that	NULL
pathogenic	NULL
(	NULL
H3	NULL
)	NULL
and	NULL
nonpathogenic	NULL
(	NULL
H310A1	NULL
)	NULL
virus	NULL
infections	NULL
selectively	NULL
activate	NULL
different	NULL
Vy	NULL
*	NULL
cell	NULL
subsets	NULL
and	NULL
that	NULL
,	NULL
again	NULL
,	NULL
Vy1	NULL
*	NULL
T	NULL
cells	NULL
cause	NULL
disease	NULL
resistance	NULL
but	NULL
Vy4~*	NULL
cells	NULL
cause	NULL
susceptibility	NULL
.	NULL

The	NULL
cytokine	NULL
profiles	NULL
of	NULL
the	NULL
Vy	NULL
cell	NULL
subsets	NULL
suggest	NULL
that	NULL
these	NULL
cells	NULL
modulate	NULL
CD4	NULL
*	NULL
-Th-cell	NULL
responses	NULL
through	NULL
the	NULL
cytokines	NULL
they	NULL
release	NULL
.	NULL

We	NULL
tested	NULL
this	NULL
hypothesis	NULL
by	NULL
transferring	NULL
Vy	NULL
subpopulations	NULL
isolated	NULL
from	NULL
BALB/c	NULL
Stat6	NULL
knockout	NULL
(	NULL
Statéko	NULL
)	NULL
and	NULL
Stat4ko	NULL
mice	NULL
into	NULL
H3	NULL
virus-infected	NULL
recipients	NULL
.	NULL

Statd4	NULL
and	NULL
Stato	NULL
are	NULL
transcription	NULL
factors	NULL
important	NULL
in	NULL
IL-12	NULL
and	NULL
IL-4	NULL
,	NULL
respectively	NULL
(	NULL
3	NULL
,	NULL
21	NULL
,	NULL
29	NULL
)	NULL
,	NULL
and	NULL
animals	NULL
lacking	NULL
Stat4	NULL
and	NULL
Stat6	NULL
have	NULL
defective	NULL
Th1-	NULL
and	NULL
Th2-cell	NULL
responses	NULL
.	NULL

Vy1*	NULL
cells	NULL
isolated	NULL
from	NULL
BALB/c	NULL
Stat4ko	NULL
mice	NULL
,	NULL
which	NULL
stain	NULL
positively	NULL
for	NULL
IL-4	NULL
,	NULL
still	NULL
suppressed	NULL
CD4	NULL
*-Thl1-cell	NULL
responses	NULL
and	NULL
myocarditis	NULL
;	NULL
the	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
same	NULL
cell	NULL
population	NULL
derived	NULL
from	NULL
Statéko	NULL
donors	NULL
was	NULL
not	NULL
suppressive	NULL
.	NULL

This	NULL
result	NULL
implies	NULL
that	NULL
the	NULL
cytokines	NULL
made	NULL
by	NULL
the	NULL
Vy	NULL
*	NULL
cell	NULL
subpopulations	NULL
are	NULL
important	NULL
in	NULL
modulating	NULL
myocarditis	NULL
susceptibility	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Mice	NULL
.	NULL

Male	NULL
BALB/cJ	NULL
,	NULL
BALB/c-Stat4	NULL
``	NULL
``	NULL
~	NULL
,	NULL
and	NULL
BALB/c-Stat6	NULL
``	NULL
``	NULL
**	NULL
``	NULL
mice	NULL
,	NULL
5	NULL
to	NULL
6	NULL
weeks	NULL
of	NULL
age	NULL
,	NULL
were	NULL
purchased	NULL
from	NULL
Jackson	NULL
Laboratories	NULL
,	NULL
Bar	NULL
Harbor	NULL
,	NULL
Maine	NULL
.	NULL

Virus	NULL
,	NULL
virus	NULL
infection	NULL
,	NULL
and	NULL
virus	NULL
titration	NULL
.	NULL

Animals	NULL
were	NULL
infected	NULL
by	NULL
intraperi-toneal	NULL
(	NULL
ip	NULL
.	NULL
)	NULL

injection	NULL
of	NULL
0.5	NULL
ml	NULL
of	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
containing	NULL
10+	NULL
PFU	NULL
of	NULL
cither	NULL
the	NULL
CVB3	NULL
H3	NULL
or	NULL
the	NULL
H310A1	NULL
variant	NULL
,	NULL
derived	NULL
from	NULL
Cos	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
infectious	NULL
cDNAs	NULL
of	NULL
this	NULL
virus	NULL
(	NULL
22	NULL
)	NULL
.	NULL

For	NULL
virus	NULL
titration	NULL
,	NULL
hearts	NULL
were	NULL
homogenized	NULL
in	NULL
0.9	NULL
ml	NULL
of	NULL
RPMI	NULL
1640	NULL
containing	NULL
100	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
100	NULL
ug	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
5	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
.	NULL

Cellular	NULL
debris	NULL
was	NULL
removed	NULL
by	NULL
centrifugation	NULL
at	NULL
1,045	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
titer	NULL
of	NULL
the	NULL
supernatant	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
plaque-forming	NULL
assay	NULL
on	NULL
HeLa	NULL
cell	NULL
mono-layers	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Antibodies	NULL
.	NULL

Antibody	NULL
class	NULL
control	NULL
(	NULL
isotype	NULL
control	NULL
)	NULL
and	NULL
antigen-specific	NULL
antibodies	NULL
were	NULL
obtained	NULL
from	NULL
PharMingen	NULL
(	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

These	NULL
included	NULL
phycoerythrin	NULL
(	NULL
PE	NULL
)	NULL
-conjugated	NULL
anti-CD3	NULL
(	NULL
clone	NULL
1742	NULL
)	NULL
;	NULL
purified	NULL
anti-TcRB	NULL
(	NULL
clone	NULL
H57-597	NULL
)	NULL
;	NULL
purified	NULL
anti-Mac3	NULL
(	NULL
clone	NULL
M3/84	NULL
)	NULL
;	NULL
purified	NULL
anti-IA	NULL
``	NULL
(	NULL
clone	NULL
39-10-8	NULL
)	NULL
;	NULL
purified	NULL
rat	NULL
anti-mouse	NULL
CD16	NULL
CD32	NULL
(	NULL
Fe	NULL
Block	NULL
,	NULL
clone	NULL
2.4G2	NULL
)	NULL
;	NULL
biotinylated	NULL
or	NULL
CyChrome-	NULL
,	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-	NULL
,	NULL
or	NULL
PE-conjugated	NULL
rat	NULL
IgG1	NULL
(	NULL
clone	NULL
R3-34	NULL
)	NULL
;	NULL
biotinylated	NULL
or	NULL
FITC-	NULL
or	NULL
PE-conjugated	NULL
rat	NULL
anti-mouse	NULL
IFN-y	NULL
(	NULL
clone	NULL
XMG	NULL
1.2	NULL
)	NULL
;	NULL
biotinylated	NULL
or	NULL
FITC-	NULL
or	NULL
PE-conjugated	NULL
rat	NULL
anti-mouse	NULL
IL-4	NULL
(	NULL
clone	NULL
BVD4-1D11	NULL
)	NULL
;	NULL
FITC-conjugated	NULL
hamster	NULL
anti-mouse	NULL
CD69	NULL
(	NULL
clone	NULL
H1.2F3	NULL
)	NULL
;	NULL
biotinylated	NULL
or	NULL
FITC-	NULL
,	NULL
PE-	NULL
,	NULL
or	NULL
CyChrome-conjugated	NULL
rat-anti-mouse	NULL
CD4	NULL
(	NULL
clone	NULL
GK	NULL
1.5	NULL
)	NULL
;	NULL
purified	NULL
or	NULL
FITC-	NULL
or	NULL
PE-conjugated	NULL
hamster	NULL
IgG	NULL
;	NULL
FITC-	NULL
or	NULL
PE-conjugated	NULL
mouse	NULL
anti-hamster	NULL
IgG	NULL
cocktail	NULL
(	NULL
clones	NULL
G70-204	NULL
and	NULL
G94-56	NULL
)	NULL
;	NULL
and	NULL
purified	NULL
or	NULL
FITC-	NULL
or	NULL
PE-conjugated	NULL
hamster-anti-y8	NULL
TeR	NULL
(	NULL
clone	NULL
GL3	NULL
)	NULL
.	NULL

Various	NULL
purified	NULL
,	NULL
FITC-	NULL
and	NULL
biotin-conjugated	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
Vy1	NULL
(	NULL
clone	NULL
2.11	NULL
)	NULL
,	NULL
Vy4	NULL
(	NULL
clone	NULL
UC3	NULL
)	NULL
,	NULL
V84	NULL
(	NULL
clone	NULL
GL2	NULL
)	NULL
,	NULL
and	NULL
V86.3	NULL
(	NULL
clone	NULL
17-C	NULL
)	NULL
were	NULL
prepared	NULL
and	NULL
tested	NULL
in	NULL
the	NULL
laboratory	NULL
of	NULL
Rebecca	NULL
O'Brien	NULL
.	NULL

CyChrome-	NULL
,	NULL
FITC-	NULL
,	NULL
and	NULL
PE-conjugated	NULL
streptavidin	NULL
was	NULL
purchased	NULL
from	NULL
PharMingen	NULL
.	NULL

Streptavidin-conjugated	NULL
Red613	NULL
was	NULL
purchased	NULL
from	NULL
Gibco	NULL
Life	NULL
Technologies	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y	NULL
.	NULL

Isolation	NULL
of	NULL
spleen	NULL
lymphocytes	NULL
.	NULL

Spleens	NULL
were	NULL
aseptically	NULL
removed	NULL
from	NULL
eu-thanized	NULL
mice	NULL
,	NULL
pressed	NULL
through	NULL
fine-mesh	NULL
screens	NULL
to	NULL
form	NULL
single-cell	NULL
suspensions	NULL
which	NULL
were	NULL
layered	NULL
over	NULL
Histopaque-1077	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

,	NULL
and	NULL
centrifuged	NULL
at	NULL
1,048	NULL
x	NULL
g	NULL
for	NULL
15	NULL
min	NULL
.	NULL

The	NULL
lymphoid	NULL
cells	NULL
at	NULL
the	NULL
interface	NULL
were	NULL
retrieved	NULL
and	NULL
counted	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

The	NULL
procedure	NULL
for	NULL
isolation	NULL
of	NULL
enriched	NULL
populations	NULL
of	NULL
Vy1	NULL
``	NULL
*	NULL
or	NULL
Vy4	NULL
*	NULL
cell	NULL
populations	NULL
has	NULL
been	NULL
published	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
splenocytes	NULL
obtained	NULL
after	NULL
Histopaque	NULL
purification	NULL
were	NULL
incubated	NULL
on	NULL
nylon	NULL
wool	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37°C	NULL
;	NULL
the	NULL
nonadherent	NULL
cells	NULL
were	NULL
retrieved	NULL
;	NULL
incubated	NULL
with	NULL
1:50	NULL
dilutions	NULL
of	NULL
Fe	NULL
Block	NULL
,	NULL
TcR	NULL
antibody	NULL
,	NULL
anti-IA®	NULL
antibody	NULL
,	NULL
anti-Mac3	NULL
antibody	NULL
,	NULL
and	NULL
either	NULL
anti-Vy1	NULL
or	NULL
anti-Vy4	NULL
antibody	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
;	NULL
washed	NULL
twice	NULL
;	NULL
and	NULL
incubated	NULL
with	NULL
a	NULL
1:50	NULL
dilution	NULL
of	NULL
mouse	NULL
anti-hamster	NULL
IgG	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
again	NULL
washed	NULL
and	NULL
incubated	NULL
with	NULL
magnetic	NULL
particles	NULL
conjugated	NULL
with	NULL
anti-mouse	NULL
IgG	NULL
and	NULL
anti-rat	NULL
IgG	NULL
(	NULL
PerSeptive	NULL
Biosystems	NULL
,	NULL
Fra-mingham	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Bound	NULL
cells	NULL
were	NULL
removed	NULL
by	NULL
passing	NULL
the	NULL
cell	NULL
suspension	NULL
over	NULL
a	NULL
magnet	NULL
.	NULL

The	NULL
remaining	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
,	NULL
divided	NULL
into	NULL
two	NULL
tubes	NULL
,	NULL
incubated	NULL
in	NULL
100	NULL
wl	NULL
of	NULL
PBS-1	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
)	NULL
containing	NULL
a	NULL
1:50	NULL
dilution	NULL
of	NULL
either	NULL
anti-Vy1	NULL
or	NULL
anti-Vy4	NULL
antibody	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
resuspended	NULL
in	NULL
RPMI	NULL
1640	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
with	NULL
100	NULL
U	NULL
of	NULL
penicillin	NULL
per	NULL
ml	NULL
,	NULL
100	NULL
jg	NULL
of	NULL
streptomycin	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
80	NULL
pg	NULL
of	NULL
recombinant	NULL
IL-2	NULL
(	NULL
PharMingen	NULL
)	NULL
per	NULL
ml	NULL
.	NULL

Cells	NULL
(	NULL
5	NULL
x	NULL
10°	NULL
)	NULL
were	NULL
added	NULL
to	NULL
tissue	NULL
culture	NULL
plates	NULL
coated	NULL
with	NULL
mouse	NULL
anti-hamster	NULL
IgG	NULL
,	NULL
centrifuged	NULL
at	NULL
100	NULL
x	NULL
g	NULL
for	NULL
5	NULL
min	NULL
,	NULL
and	NULL
incubated	NULL
at	NULL
37°C	NULL
in	NULL
a	NULL
humidified	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
incubator	NULL
for	NULL
3	NULL
days	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
retrieved	NULL
,	NULL
centrifuged	NULL
on	NULL
Histopaque	NULL
to	NULL
remove	NULL
dead	NULL
cells	NULL
,	NULL
and	NULL
counted	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
,	NULL
and	NULL
an	NULL
aliquot	NULL
was	NULL
surface	NULL
stained	NULL
with	NULL
anti-CD3	NULL
and	NULL
either	NULL
anti-Vy1	NULL
or	NULL
anti-Vy4	NULL
antibodies	NULL
to	NULL
determine	NULL
purity	NULL
.	NULL

Figure	NULL
1	NULL
shows	NULL
a	NULL
representative	NULL
flow	NULL
diagram	NULL
of	NULL
Vy1*	NULL
enriched	NULL
cells	NULL
obtained	NULL
by	NULL
this	NULL
protocol	NULL
.	NULL

Purity	NULL
of	NULL
populations	NULL
ranged	NULL
from	NULL
65	NULL
to	NULL
78	NULL
%	NULL
Vy1	NULL
CD3	NULL
*	NULL
or	NULL
Vy4	NULL
CD3*	NULL
cells	NULL
for	NULL
all	NULL
populations	NULL
.	NULL

Adoptive	NULL
transfer	NULL
of	NULL
Vy	NULL
cells	NULL
.	NULL

Vy1	NULL
``	NULL
*	NULL
or	NULL
Vy4~*	NULL
cells	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
PBS	NULL
,	NULL
resuspended	NULL
to	NULL
5	NULL
x	NULL
10°	NULL
cells	NULL
in	NULL
0.2	NULL
ml	NULL
of	NULL
PBS	NULL
,	NULL
and	NULL
injected	NULL
intravenously	NULL
(	NULL
i.v	NULL
.	NULL
)	NULL

through	NULL
the	NULL
tail	NULL
vein	NULL
of	NULL
H3	NULL
virus-infected	NULL
BALB/c	NULL
recipient	NULL
mice	NULL
on	NULL
the	NULL
third	NULL
day	NULL
after	NULL
infection	NULL
.	NULL

Animals	NULL
were	NULL
killed	NULL
on	NULL
day	NULL
7	NULL
after	NULL
infection	NULL
.	NULL

Control	NULL
mice	NULL
received	NULL
PBS	NULL
alone	NULL
.	NULL

y8*	NULL
T	NULL
CELLS	NULL
IN	NULL
MYOCARDITIS	NULL
-	NULL
5861	NULL
L	NULL
LUO	NULL
CD3	NULL
--	NULL
-	NULL
>	NULL
i000	NULL
*	NULL
tomtom	NULL
t	NULL
&	NULL
1	NULL
1080	NULL
Vy1	NULL
me-	NULL
]	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Representative	NULL
purity	NULL
of	NULL
Vy1*	NULL
cells	NULL
isolated	NULL
from	NULL
the	NULL
spleens	NULL
of	NULL
H3	NULL
virus-infected	NULL
mice	NULL
.	NULL

BALB/c	NULL
Stat4ko	NULL
mice	NULL
were	NULL
infected	NULL
with	NULL
H3	NULL
virus	NULL
and	NULL
killed	NULL
5	NULL
days	NULL
later	NULL
.	NULL

Spleens	NULL
were	NULL
removed	NULL
,	NULL
depleted	NULL
of	NULL
red	NULL
blood	NULL
cells	NULL
,	NULL
and	NULL
enriched	NULL
for	NULL
y8	NULL
*	NULL
T	NULL
cells	NULL
by	NULL
negative	NULL
selection	NULL
of	NULL
aB	NULL
*	NULL
,	NULL
Mac3	NULL
*	NULL
,	NULL
and	NULL
IA**	NULL
cells	NULL
using	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
these	NULL
cells	NULL
and	NULL
antibody-coated	NULL
magnetic	NULL
particles	NULL
.	NULL

The	NULL
remaining	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
anti-Vy1	NULL
monoclonal	NULL
antibody	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
added	NULL
to	NULL
tissue	NULL
culture	NULL
plates	NULL
coated	NULL
with	NULL
anti-hamster	NULL
IgG	NULL
antibody	NULL
for	NULL
3	NULL
days	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
retrieved	NULL
,	NULL
washed	NULL
,	NULL
incubated	NULL
with	NULL
PE-conjugated	NULL
anti-CD3	NULL
antibody	NULL
and	NULL
biotinylated	NULL
anti-Vy1	NULL
antibody	NULL
,	NULL
washed	NULL
,	NULL
incubated	NULL
with	NULL
FITC-conjugated	NULL
streptavidin	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
for	NULL
stained	NULL
cells	NULL
.	NULL

Numbers	NULL
in	NULL
the	NULL
upper	NULL
right-hand	NULL
corner	NULL
indicate	NULL
the	NULL
percentages	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
quadrants	NULL
.	NULL

Flow	NULL
cytometry	NULL
.	NULL

Cells	NULL
were	NULL
cither	NULL
stained	NULL
directly	NULL
for	NULL
cell	NULL
surface	NULL
markers	NULL
or	NULL
cultured	NULL
in	NULL
medium	NULL
containing	NULL
10	NULL
ug	NULL
of	NULL
brefeldin	NULL
A	NULL
per	NULL
ml	NULL
,	NULL
50	NULL
ng	NULL
of	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
per	NULL
ml	NULL
,	NULL
and	NULL
500	NULL
ng	NULL
of	NULL
ionomycin	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
per	NULL
ml	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37°C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
for	NULL
intracellular	NULL
cytokine	NULL
analysis	NULL
.	NULL

For	NULL
surface	NULL
staining	NULL
,	NULL
cells	NULL
were	NULL
resuspended	NULL
in	NULL
PBS	NULL
containing	NULL
1	NULL
%	NULL
BSA	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
a	NULL
1:100	NULL
dilution	NULL
of	NULL
Fe	NULL
Block	NULL
,	NULL
and	NULL
1:100	NULL
dilutions	NULL
of	NULL
either	NULL
fluorochrome-conjugated	NULL
or	NULL
biotinylated	NULL
antibodies	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
,	NULL
where	NULL
applicable	NULL
(	NULL
when	NULL
biotinylated	NULL
antibodies	NULL
were	NULL
used	NULL
)	NULL
,	NULL
resuspended	NULL
in	NULL
PBS-BSA	NULL
containing	NULL
a	NULL
1:50	NULL
dilution	NULL
of	NULL
streptavidin-fluorochrome	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
and	NULL
resuspended	NULL
in	NULL
2	NULL
%	NULL
paraformaldehyde	NULL
.	NULL

For	NULL
intracellular	NULL
staining	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
after	NULL
the	NULL
4-h	NULL
culture	NULL
described	NULL
above	NULL
in	NULL
PBS-BSA	NULL
containing	NULL
10	NULL
pg	NULL
of	NULL
brefeldin	NULL
A	NULL
per	NULL
ml	NULL
and	NULL
surface	NULL
stained	NULL
as	NULL
described	NULL
above	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
brefeldin	NULL
A	NULL
was	NULL
maintained	NULL
throughout	NULL
the	NULL
labeling	NULL
procedure	NULL
.	NULL

After	NULL
surface	NULL
staining	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
fixed	NULL
in	NULL
2	NULL
%	NULL
paraformaldehyde	NULL
for	NULL
10	NULL
min	NULL
;	NULL
thereafter	NULL
,	NULL
brefeldin	NULL
A	NULL
was	NULL
not	NULL
required	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
then	NULL
washed	NULL
once	NULL
in	NULL
PBS-BSA	NULL
buffer	NULL
,	NULL
incubated	NULL
for	NULL
10	NULL
min	NULL
in	NULL
PBS-BSA	NULL
buffer	NULL
containing	NULL
0.5	NULL
%	NULL
saponin	NULL
,	NULL
and	NULL
stained	NULL
for	NULL
intracellular	NULL
molecules	NULL
and	NULL
cytokines	NULL
,	NULL
as	NULL
indicated	NULL
in	NULL
Results	NULL
,	NULL
by	NULL
resuspending	NULL
the	NULL
cells	NULL
in	NULL
PBS-BSA-saponin	NULL
containing	NULL
1:100	NULL
dilutions	NULL
of	NULL
Fe	NULL
Block	NULL
and	NULL
the	NULL
biotinylated	NULL
or	NULL
fluorochrome-conjugated	NULL
antibodies	NULL
and	NULL
50	NULL
pg	NULL
of	NULL
rat	NULL
polyclonal	NULL
IgG	NULL
(	NULL
Zymed	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
Calif.	NULL
)	NULL
per	NULL
ml	NULL
.	NULL

After	NULL
incubation	NULL
for	NULL
30	NULL
min	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
PBS-BSA-saponin	NULL
and	NULL
once	NULL
in	NULL
saponin-free	NULL
PBS-BSA	NULL
to	NULL
close	NULL
the	NULL
membrane	NULL
and	NULL
then	NULL
resuspended	NULL
in	NULL
PBS	NULL
containing	NULL
2	NULL
%	NULL
paraformaldehyde	NULL
.	NULL

Positive	NULL
controls	NULL
for	NULL
cytokine	NULL
staining	NULL
were	NULL
2.5	NULL
X	NULL
10°	NULL
cells	NULL
of	NULL
either	NULL
MIC-1	NULL
(	NULL
IFN-y	NULL
)	NULL
-	NULL
or	NULL
MIC-2	NULL
(	NULL
IL-4	NULL
)	NULL
-fixed	NULL
cells	NULL
obtained	NULL
from	NULL
PharMingen	NULL
.	NULL

Negative	NULL
controls	NULL
were	NULL
biotinylated	NULL
,	NULL
and	NULL
fluorochrome-conjugated	NULL
species-	NULL
and	NULL
isotype-matched	NULL
Igs	NULL
and	NULL
streptavidin-fluorochrome	NULL
combinations	NULL
were	NULL
as	NULL
used	NULL
in	NULL
specific-antibody	NULL
staining	NULL
samples	NULL
.	NULL

Stained	NULL
cell	NULL
populations	NULL
were	NULL
analyzed	NULL
using	NULL
a	NULL
Coulter	NULL
Epics	NULL
Elite	NULL
instrument	NULL
with	NULL
a	NULL
single	NULL
excitation	NULL
wavelength	NULL
(	NULL
488	NULL
nm	NULL
)	NULL
and	NULL
band	NULL
filters	NULL
for	NULL
PE	NULL
(	NULL
wavelength	NULL
,	NULL
575	NULL
nm	NULL
)	NULL
,	NULL
FITC	NULL
(	NULL
525	NULL
nm	NULL
)	NULL
,	NULL
Red613	NULL
(	NULL
613	NULL
nm	NULL
)	NULL
,	NULL
and	NULL
CyChrome	NULL
(	NULL
670	NULL
nm	NULL
)	NULL
.	NULL

Each	NULL
sample	NULL
population	NULL
was	NULL
classified	NULL
for	NULL
cell	NULL
size	NULL
(	NULL
forward	NULL
scatter	NULL
)	NULL
and	NULL
complexity	NULL
(	NULL
side	NULL
scatter	NULL
)	NULL
and	NULL
then	NULL
gated	NULL
on	NULL
a	NULL
population	NULL
of	NULL
interest	NULL
.	NULL

At	NULL
least	NULL
10,000	NULL
cells	NULL
were	NULL
evaluated	NULL
for	NULL
each	NULL
sample	NULL
.	NULL

Criteria	NULL
for	NULL
positive	NULL
staining	NULL
were	NULL
established	NULL
using	NULL
isotype	NULL
controls	NULL
.	NULL

The	NULL
results	NULL
were	NULL
expressed	NULL
in	NULL
one	NULL
of	NULL
two	NULL
ways	NULL
:	NULL
cither	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
total	NULL
splenocytes	NULL
staining	NULL
for	NULL
a	NULL
particular	NULL
marker	NULL
minus	NULL
the	NULL
number	NULL
of	NULL
splenocytes	NULL
in	NULL
the	NULL
isotype	NULL
control	NULL
or	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
a	NULL
specific	NULL
population	NULL
of	NULL
cells	NULL
which	NULL
stained	NULL
positively	NULL
for	NULL
each	NULL
marker	NULL
[	NULL
for	NULL
example	NULL
,	NULL
the	NULL
percentage	NULL
of	NULL
CD4*	NULL
cells	NULL
staining	NULL
for	NULL
IL-4	NULL
represents	NULL
CD4*	NULL
IL-4	NULL
*	NULL
cells/	NULL
(	NULL
CD4*	NULL
IL-4~	NULL
+	NULL
CD4*	NULL
IL-4*	NULL
cells	NULL
)	NULL
x	NULL
100	NULL
]	NULL
.	NULL

5862	NULL
HUBER	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

TABLE	NULL
1	NULL
.	NULL

Myocarditis	NULL
in	NULL
mice	NULL
``	NULL
%	NULL
of	NULL
myocardium	NULL
Cardiac	NULL
virus	NULL
titer	NULL
Total	NULL
no	NULL
.	NULL

of	NULL
lymphocytes	NULL
%	NULL
of	NULL
CD4*	NULL
cells	NULL
%	NULL
of	NULL
CD4*	NULL
cells	NULL
which	NULL
are	NULL
:	NULL
Treatment	NULL
inflamed	NULL
(	NULL
log	NULL
10	NULL
PFU	NULL
)	NULL
in	NULL
spleen	NULL
(	NULL
10°	NULL
)	NULL
in	NULL
spleen	NULL
IEN-y*	NULL
1L-4*	NULL
None	NULL
0	NULL
+	NULL
0	NULL
16.53	NULL
+£2.17	NULL
29.7	NULL
+	NULL
3.5	NULL
1.3	NULL
+	NULL
0.8	NULL
2.9	NULL
+	NULL
1.5	NULL
H3	NULL
virus	NULL
7.9	NULL
+	NULL
0.9	NULL
%	NULL
5.01	NULL
+	NULL
0.17	NULL
#	NULL
11.93	NULL
+	NULL
1.02	NULL
24.3	NULL
+	NULL
1.2	NULL
%	NULL
10.1	NULL
+	NULL
3.1	NULL
«	NULL
2.3	NULL
+	NULL
0.7	NULL
%	NULL
H310A1	NULL
virus	NULL
1.3	NULL
+	NULL
0.5	NULL
6.33	NULL
+	NULL
0.25	NULL
15.33	NULL
+	NULL
1.79	NULL
27.7	NULL
£	NULL
1.0	NULL
1.9	NULL
+	NULL
1.0	NULL
9.4	NULL
+	NULL
2.3	NULL
``	NULL
BALB/c	NULL
male	NULL
mice	NULL
were	NULL
either	NULL
not	NULL
infected	NULL
or	NULL
infected	NULL
with	NULL
10°	NULL
PFU	NULL
of	NULL
H3	NULL
or	NULL
H310A1	NULL
virus	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
PBS	NULL
by	NULL
i.p	NULL
.	NULL

injection	NULL
.	NULL

Animals	NULL
were	NULL
killed	NULL
7	NULL
days	NULL
after	NULL
infection	NULL
.	NULL

Hearts	NULL
were	NULL
divided	NULL
,	NULL
and	NULL
half	NULL
were	NULL
evaluated	NULL
by	NULL
image	NULL
analysis	NULL
for	NULL
myocarditis	NULL
and	NULL
half	NULL
were	NULL
used	NULL
to	NULL
determine	NULL
the	NULL
titer	NULL
of	NULL
virus	NULL
.	NULL

Spleens	NULL
were	NULL
retrieved	NULL
,	NULL
processed	NULL
for	NULL
lymphoid	NULL
cells	NULL
,	NULL
and	NULL
counted	NULL
by	NULL
trypan	NULL
blue	NULL
exclusion	NULL
.	NULL

The	NULL
lymphoid	NULL
cells	NULL
from	NULL
individual	NULL
animals	NULL
were	NULL
stained	NULL
for	NULL
surface	NULL
expression	NULL
of	NULL
CD4	NULL
and	NULL
for	NULL
intracellular	NULL
expression	NULL
of	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
using	NULL
three-color	NULL
flow	NULL
analysis	NULL
.	NULL

Values	NULL
are	NULL
means	NULL
+	NULL
SEM	NULL
of	NULL
results	NULL
with	NULL
4	NULL
to	NULL
10	NULL
mice	NULL
per	NULL
group	NULL
.	NULL

*	NULL
,	NULL
value	NULL
significantly	NULL
different	NULL
than	NULL
that	NULL
for	NULL
H310A	NULL
virus-infected	NULL
mice	NULL
at	NULL
a	NULL
P	NULL
of	NULL
=0.05	NULL
.	NULL

Each	NULL
experiment	NULL
was	NULL
repeated	NULL
at	NULL
least	NULL
two	NULL
times	NULL
,	NULL
and	NULL
the	NULL
data	NULL
from	NULL
a	NULL
representative	NULL
experiment	NULL
are	NULL
presented	NULL
.	NULL

Histology	NULL
.	NULL

Hearts	NULL
were	NULL
removed	NULL
,	NULL
fixed	NULL
in	NULL
10	NULL
%	NULL
buffered	NULL
formalin	NULL
,	NULL
paraffin	NULL
embedded	NULL
,	NULL
sectioned	NULL
,	NULL
and	NULL
stained	NULL
with	NULL
hematoxylin	NULL
and	NULL
eosin	NULL
.	NULL

Stained	NULL
sections	NULL
were	NULL
evaluated	NULL
for	NULL
myocarditis	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Statistics	NULL
.	NULL

Statistical	NULL
evaluation	NULL
was	NULL
performed	NULL
using	NULL
the	NULL
Wilcoxon	NULL
ranked-score	NULL
method	NULL
.	NULL

RESULTS	NULL
Evaluation	NULL
of	NULL
subpopulations	NULL
of	NULL
y8¢*	NULL
T	NULL
cells	NULL
in	NULL
mice	NULL
with	NULL
myocarditis	NULL
.	NULL

Table	NULL
1	NULL
shows	NULL
that	NULL
BALB/c	NULL
mice	NULL
infected	NULL
with	NULL
H3	NULL
virus	NULL
develop	NULL
severe	NULL
myocardial	NULL
inflammation	NULL
(	NULL
7.9	NULL
%	NULL
of	NULL
the	NULL
myocardium	NULL
inflamed	NULL
)	NULL
but	NULL
that	NULL
mice	NULL
given	NULL
H310A1	NULL
virus	NULL
have	NULL
little	NULL
myocarditis	NULL
(	NULL
1.3	NULL
%	NULL
of	NULL
the	NULL
myocardium	NULL
inflamed	NULL
)	NULL
.	NULL

Cardiac	NULL
virus	NULL
titers	NULL
were	NULL
increased	NULL
in	NULL
animals	NULL
infected	NULL
with	NULL
H310A¥1	NULL
virus	NULL
,	NULL
compared	NULL
to	NULL
those	NULL
in	NULL
H3	NULL
virus-infected	NULL
mice	NULL
,	NULL
even	NULL
though	NULL
H310A1-infected	NULL
animals	NULL
had	NULL
minimal	NULL
myocarditis	NULL
.	NULL

Numbers	NULL
of	NULL
CD4	NULL
*	NULL
IFN-y	NULL
*	NULL
cells	NULL
in	NULL
the	NULL
spleen	NULL
were	NULL
increased	NULL
in	NULL
H3	NULL
virus-infected	NULL
mice	NULL
compared	NULL
to	NULL
numbers	NULL
in	NULL
H310A¥1	NULL
virus-infected	NULL
mice	NULL
,	NULL
while	NULL
numbers	NULL
of	NULL
CD4	NULL
*	NULL
IL-4*	NULL
cells	NULL
were	NULL
re-duced	NULL
.	NULL

Figure	NULL
2	NULL
shows	NULL
representative	NULL
intracellular	NULL
cytokine	NULL
(	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
)	NULL
staining	NULL
patterns	NULL
in	NULL
these	NULL
animals	NULL
after	NULL
gating	NULL
on	NULL
the	NULL
CD4	NULL
*	NULL
-cell	NULL
population	NULL
.	NULL

H310A¥1	NULL
virus	NULL
infection	NULL
did	NULL
not	NULL
increase	NULL
the	NULL
number	NULL
of	NULL
Th1	NULL
cells	NULL
relative	NULL
to	NULL
those	NULL
found	NULL
in	NULL
uninfected	NULL
mice	NULL
but	NULL
did	NULL
increase	NULL
the	NULL
number	NULL
of	NULL
CD4*	NULL
IL-4~*	NULL
cells	NULL
in	NULL
the	NULL
spleen	NULL
(	NULL
from	NULL
2.4	NULL
%	NULL
of	NULL
cells	NULL
in	NULL
normal	NULL
to	NULL
8.5	NULL
%	NULL
of	NULL
cells	NULL
in	NULL
H310A1	NULL
virus-infected	NULL
animals	NULL
)	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
the	NULL
relative	NULL
proportions	NULL
of	NULL
Vy1	NULL
and	NULL
Vy4	NULL
subpopulations	NULL
in	NULL
H3	NULL
and	NULL
H310A¥1	NULL
virus-infected	NULL
BALB/c	NULL
mice	NULL
(	NULL
Table	NULL
2	NULL
)	NULL
.	NULL

H3	NULL
virus	NULL
infection	NULL
resulted	NULL
in	NULL
an	NULL
approximately	NULL
threefold	NULL
increase	NULL
in	NULL
the	NULL
percentage	NULL
of	NULL
splenic	NULL
y8¢	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
the	NULL
percentage	NULL
of	NULL
these	NULL
cells	NULL
in	NULL
H310A1	NULL
virus-infected	NULL
mice	NULL
stayed	NULL
approximately	NULL
the	NULL
same	NULL
as	NULL
in	NULL
uninfected	NULL
BALB/c	NULL
animals	NULL
.	NULL

At	NULL
the	NULL
same	NULL
time	NULL
,	NULL
numbers	NULL
of	NULL
Vy	NULL
4	NULL
*	NULL
cells	NULL
were	NULL
preferentially	NULL
increased	NULL
in	NULL
H3	NULL
virus-infected	NULL
mice	NULL
(	NULL
by	NULL
sevenfold	NULL
)	NULL
but	NULL
remained	NULL
unaltered	NULL
in	NULL
H310A¥1-infected	NULL
mice	NULL
compared	NULL
to	NULL
numbers	NULL
in	NULL
uninfected	NULL
animals	NULL
.	NULL

Approximately	NULL
40	NULL
%	NULL
of	NULL
the	NULL
Vy4	NULL
*	NULL
-cell	NULL
population	NULL
in	NULL
H3	NULL
virus-infected	NULL
animals	NULL
was	NULL
activated	NULL
as	NULL
assessed	NULL
by	NULL
CD69	NULL
expression	NULL
.	NULL

Both	NULL
H3	NULL
and	NULL
H310A¥1	NULL
virus-infected	NULL
animals	NULL
showed	NULL
increases	NULL
in	NULL
percentages	NULL
of	NULL
Vy1*	NULL
cells	NULL
.	NULL

Interestingly	NULL
,	NULL
in	NULL
both	NULL
H3	NULL
and	NULL
H310A¥1	NULL
virus-infected	NULL
groups	NULL
,	NULL
V84	NULL
expression	NULL
dominated	NULL
.	NULL

Intracellular	NULL
cytokine	NULL
staining	NULL
of	NULL
the	NULL
Vy-stained	NULL
cell	NULL
populations	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
revealed	NULL
that	NULL
,	NULL
although	NULL
neither	NULL
Vy1*	NULL
nor	NULL
cells	NULL
from	NULL
uninfected	NULL
mice	NULL
showed	NULL
much	NULL
intracellular	NULL
cytokine	NULL
staining	NULL
,	NULL
cells	NULL
from	NULL
H3-infected	NULL
mice	NULL
showed	NULL
substantially	NULL
increased	NULL
cytokine	NULL
expression	NULL
.	NULL

About	NULL
20	NULL
%	NULL
of	NULL
the	NULL
Vy1	NULL
cells	NULL
from	NULL
H3	NULL
Uninfected	NULL
H3-Infected	NULL
H310A¥1l-Infected	NULL
®	NULL
®	NULL
>	NULL
Q	NULL
:	NULL
-	NULL
&	NULL
®	NULL
®	NULL
®	NULL
7	NULL
``	NULL
3	NULL
0.8|	NULL
0.1	NULL
.	NULL

3	NULL
5.2	NULL
0.27	NULL
a	NULL
:	NULL
0.6	NULL
|	NULL
0.2	NULL
96.7	NULL
)	NULL
2.4	NULL
91.6	NULL
)	NULL
3.2	NULL
=	NULL
90.4	NULL
|	NULL
8.5	NULL
3	NULL
3	NULL
2°	NULL
a	NULL
dea	NULL
:	NULL
«	NULL
a	NULL
.	NULL

|	NULL
Z	NULL
*	NULL
PTAC	NULL
T	NULL
TTI	NULL
*	NULL
“	NULL
ﬁmm	NULL
TT	NULL
+7	NULL
PT	NULL
TMT	NULL
LL	NULL
&	NULL
1	NULL
1000	NULL
&	NULL
1	NULL
1090	NULL
&	NULL
A	NULL
1900	NULL
)	NULL
--	NULL
IL-4	NULL
-	NULL
ad	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Intracellular	NULL
cytokine	NULL
staining	NULL
of	NULL
CD4*	NULL
splenocytes	NULL
.	NULL

Single-cell	NULL
suspensions	NULL
from	NULL
individual	NULL
mice	NULL
were	NULL
stimulated	NULL
for	NULL
4	NULL
h	NULL
at	NULL
37°C	NULL
with	NULL
PMA	NULL
,	NULL
ionomycin	NULL
,	NULL
and	NULL
brefeldin	NULL
A	NULL
;	NULL
stained	NULL
for	NULL
CD4	NULL
surface	NULL
marker	NULL
;	NULL
fixed	NULL
in	NULL
paraformaldehyde	NULL
;	NULL
permeabilized	NULL
;	NULL
and	NULL
stained	NULL
for	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
.	NULL

Cells	NULL
were	NULL
gated	NULL
in	NULL
a	NULL
flow	NULL
cytometer	NULL
on	NULL
the	NULL
CD4	NULL
*	NULL
cell	NULL
population	NULL
and	NULL
then	NULL
analyzed	NULL
for	NULL
cytokine-positive	NULL
subsets	NULL
.	NULL

Numbers	NULL
in	NULL
the	NULL
upper	NULL
right-hand	NULL
corner	NULL
represent	NULL
the	NULL
percentages	NULL
of	NULL
CD4*	NULL
splenocytes	NULL
in	NULL
the	NULL
quadrants	NULL
.	NULL

Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
y8*	NULL
T	NULL
CELLS	NULL
IN	NULL
MYOCARDITIS	NULL
-	NULL
5863	NULL
TABLE	NULL
2	NULL
.	NULL

Proportions	NULL
of	NULL
Vy1	NULL
and	NULL
Vy4	NULL
subpopulations	NULL
in	NULL
H3-	NULL
and	NULL
H310A1-infected	NULL
BALB/c	NULL
mice	NULL
``	NULL
%	NULL
of	NULL
splenocytes	NULL
which	NULL
stained	NULL
positively	NULL
for	NULL
:	NULL
Mice	NULL
y8	NULL
y8	NULL
Vy1	NULL
v8	NULL
Vy4	NULL
y8	NULL
Vy1	NULL
V84	NULL
-	NULL
y8	NULL
Vy4	NULL
V84	NULL
-	NULL
y8	NULL
Vy1	NULL
V863	NULL
-	NULL
48	NULL
Vy4	NULL
V86.3	NULL
-	NULL
y8	NULL
Vy1	NULL
CD69	NULL
-	NULL
y8	NULL
Vy4	NULL
CD69	NULL
Uninfected	NULL
2.6	NULL
+	NULL
0.8	NULL
14+	NULL
1.0	NULL
0.7	NULL
+03	NULL
0.5	NULL
+	NULL
0.2	NULL
0.3	NULL
+	NULL
0.2	NULL
0.3	NULL
+	NULL
0.1	NULL
0.1	NULL
+	NULL
0.1	NULL
0.3	NULL
+	NULL
0.1	NULL
0.2	NULL
+	NULL
0.1	NULL
H3	NULL
infected	NULL
8.7	NULL
+	NULL
2.5	NULL
%	NULL
-	NULL
3.6	NULL
£	NULL
1.4	NULL
4.9	NULL
+	NULL
1.8	NULL
%	NULL
1.1	NULL
+	NULL
0.7	NULL
4.4	NULL
+	NULL
1.7	NULL
%	NULL
0.3	NULL
+	NULL
0.1	NULL
0.5	NULL
+	NULL
0.3	NULL
1.0	NULL
+	NULL
0.5	NULL
2.0	NULL
+	NULL
0.4	NULL
%	NULL
H310A1	NULL
infected	NULL
-	NULL
3.8	NULL
+	NULL
2.1	NULL
3.0	NULL
+	NULL
1.6	NULL
1.2	NULL
+	NULL
0.6	NULL
1.3	NULL
+	NULL
0.7	NULL
0.6	NULL
+	NULL
0.6	NULL
0.4	NULL
+	NULL
0.2	NULL
0.6	NULL
+	NULL
0.4	NULL
0.6	NULL
+	NULL
0.2	NULL
1.0	NULL
+	NULL
0.5	NULL
``	NULL
Splenocytes	NULL
were	NULL
stained	NULL
with	NULL
fluorochrome-labeled	NULL
antibodies	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
for	NULL
the	NULL
percentages	NULL
of	NULL
total	NULL
splenocytes	NULL
that	NULL
positively	NULL
stained	NULL
for	NULL
the	NULL
markers	NULL
indicated	NULL
.	NULL

Results	NULL
are	NULL
means	NULL
+	NULL
SEM	NULL
of	NULL
values	NULL
for	NULL
individual	NULL
mice	NULL
in	NULL
each	NULL
group	NULL
.	NULL

*	NULL
,	NULL
value	NULL
different	NULL
than	NULL
that	NULL
for	NULL
the	NULL
uninfected	NULL
group	NULL
at	NULL
a	NULL
P	NULL
of	NULL
=0.05	NULL
.	NULL

infected	NULL
animals	NULL
produced	NULL
low	NULL
levels	NULL
of	NULL
IFN-y	NULL
,	NULL
or	NULL
both	NULL
IFN-y	NULL
Antibody-mediated	NULL
depletion	NULL
of	NULL
Vy	NULL
cell	NULL
subsets	NULL
in	NULL
vivo	NULL
.	NULL

To	NULL
and	NULL
IL-4	NULL
,	NULL
whereas	NULL
over	NULL
half	NULL
of	NULL
the	NULL
Vy4	NULL
*	NULL
subpopulation	NULL
showed	NULL
evaluate	NULL
whether	NULL
Vy	NULL
populations	NULL
differentially	NULL
affect	NULL
myocar-strong	NULL
IFN-y	NULL
production	NULL
,	NULL
again	NULL
with	NULL
low	NULL
levels	NULL
of	NULL
IL-4	NULL
in	NULL
some	NULL
ditis	NULL
susceptibility	NULL
,	NULL
BALB/c	NULL
mice	NULL
were	NULL
depleted	NULL
of	NULL
each	NULL
subset	NULL
cells	NULL
.	NULL

H310A1	NULL
virus	NULL
infection	NULL
resulted	NULL
in	NULL
more	NULL
cytokine-pro-	NULL
by	NULL
injection	NULL
of	NULL
300	NULL
ug	NULL
of	NULL
monoclonal	NULL
hamster	NULL
IgG	NULL
,	NULL
anti-	NULL
Vy1	NULL
,	NULL
or	NULL
ducing	NULL
y8¢	NULL
T	NULL
cells	NULL
than	NULL
in	NULL
uninfected	NULL
mice	NULL
but	NULL
less	NULL
than	NULL
in	NULL
anti-Vy4	NULL
antibodies	NULL
i.v	NULL
.	NULL

through	NULL
their	NULL
tail	NULL
veins	NULL
.	NULL

Three	NULL
days	NULL
H3-infected	NULL
animals	NULL
.	NULL

Of	NULL
these	NULL
,	NULL
both	NULL
and	NULL
Vy1*	NULL
cells	NULL
later	NULL
,	NULL
the	NULL
mice	NULL
were	NULL
injected	NULL
i.p	NULL
.	NULL

with	NULL
H3	NULL
or	NULL
H310A¥1	NULL
.	NULL

Seven	NULL
stained	NULL
primarily	NULL
for	NULL
IFN-y	NULL
.	NULL

days	NULL
after	NULL
infection	NULL
,	NULL
mice	NULL
were	NULL
killed	NULL
.	NULL

Figure	NULL
4	NULL
shows	NULL
myocar-	NULL
Vy1l	NULL
A	NULL
L	NULL
-	NULL
4.1	NULL
]	NULL
0.8	NULL
2	NULL
-_	NULL
95.0	NULL
]	NULL
0.2	NULL
105	NULL
Uninfected	NULL
10°	NULL
10°	NULL
10	NULL
!	NULL

I	NULL
”	NULL
IIIII'ﬂTrllleI	NULL
[	NULL
Hm	NULL
T	NULL
TTT	NULL
10	NULL
'	NULL
10	NULL
?	NULL

10+	NULL
19	NULL
'	NULL
-	NULL
116	NULL
|	NULL
76	NULL
2	NULL
80.5	NULL
|	NULL
13	NULL
103	NULL
10°	NULL
1	NULL
appro	NULL
a	NULL
ormal	NULL
|	NULL
H3-Infected	NULL
10	NULL
'	NULL
Tiimif	NULL
-rf	NULL
mig	NULL
mm	NULL
10	NULL
'	NULL
10	NULL
'	NULL
10	NULL
'	NULL
10	NULL
'	NULL
ermmm	NULL
T	NULL
10	NULL
'	NULL
10	NULL
*	NULL
10	NULL
+	NULL
10	NULL
'	NULL
#	NULL
]	NULL
-	NULL
g	NULL
oo	NULL
lfs	NULL
-	NULL
moloal	NULL
Infected	NULL
IFNy	NULL
1m	NULL
”	NULL
UNI	NULL
l	NULL
IIITHII	NULL
p	NULL
WWI—mm	NULL
IL4	NULL
10	NULL
t	NULL
0	NULL
gor	NULL
0	NULL
aoc	NULL
_	NULL
90	NULL
105	NULL
oo	NULL
4g4	NULL
0	NULL
49	NULL
}	NULL
,	NULL
10	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Cytokine	NULL
staining	NULL
of	NULL
Vy1	NULL
and	NULL
Vy4	NULL
subsets	NULL
in	NULL
uninfected	NULL
H3-	NULL
and	NULL
H310A1-infected	NULL
BALB/c	NULL
mice	NULL
.	NULL

Spleen	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
4	NULL
h	NULL
with	NULL
PMA	NULL
,	NULL
ionomycin	NULL
,	NULL
and	NULL
brefeldin	NULL
A	NULL
;	NULL
surface	NULL
stained	NULL
for	NULL
either	NULL
Vy1	NULL
or	NULL
Vy4	NULL
;	NULL
and	NULL
then	NULL
intracellularly	NULL
stained	NULL
for	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
.	NULL

Cells	NULL
were	NULL
gated	NULL
on	NULL
the	NULL
Vy1	NULL
or	NULL
Vy4	NULL
stained	NULL
population	NULL
and	NULL
then	NULL
analyzed	NULL
for	NULL
cytokine-positive	NULL
subpopulations	NULL
.	NULL

Numbers	NULL
in	NULL
the	NULL
upper	NULL
right-hand	NULL
corner	NULL
represent	NULL
the	NULL
percentages	NULL
of	NULL
gated	NULL
cells	NULL
in	NULL
the	NULL
quadrants	NULL
.	NULL

5864	NULL
HUBER	NULL
ET	NULL
AL	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

18	NULL
15	NULL
-I-	NULL
12	NULL
C	NULL
Hamster	NULL
IgG	NULL
H	NULL
Anti-Vgi	NULL
|	NULL
G	NULL
anti-Ved4	NULL
%	NULL
Myocardium	NULL
Inflamed	NULL
Uninfected	NULL
H3-Infected	NULL
I	NULL
H310A1-Infected	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Myocarditis	NULL
in	NULL
antibody-treated	NULL
mice	NULL
.	NULL

BALB/c	NULL
mice	NULL
were	NULL
injected	NULL
i.v	NULL
.	NULL

with	NULL
200	NULL
ug	NULL
of	NULL
hamster	NULL
IgG	NULL
,	NULL
anti-Vy1	NULL
,	NULL
or	NULL
anti-Vy4	NULL
monoclonal	NULL
antibodies	NULL
3	NULL
days	NULL
prior	NULL
to	NULL
i.p	NULL
.	NULL

infection	NULL
with	NULL
either	NULL
H3	NULL
or	NULL
H310A1	NULL
virus	NULL
.	NULL

All	NULL
animals	NULL
were	NULL
killed	NULL
7	NULL
days	NULL
after	NULL
infection	NULL
(	NULL
10	NULL
days	NULL
after	NULL
antibody	NULL
administration	NULL
)	NULL
,	NULL
and	NULL
hearts	NULL
were	NULL
evaluated	NULL
for	NULL
myocarditis	NULL
.	NULL

Results	NULL
represent	NULL
means	NULL
*	NULL
standard	NULL
errors	NULL
of	NULL
the	NULL
means	NULL
(	NULL
SEM	NULL
)	NULL
of	NULL
results	NULL
with	NULL
at	NULL
least	NULL
four	NULL
mice	NULL
per	NULL
group	NULL
.	NULL

*	NULL
,	NULL
P	NULL
=	NULL
0.05	NULL
compared	NULL
to	NULL
results	NULL
for	NULL
hamster	NULL
IgG-treated	NULL
animals	NULL
.	NULL

dial	NULL
inflammation	NULL
in	NULL
the	NULL
various	NULL
groups	NULL
.	NULL

In	NULL
H3-infected	NULL
mice	NULL
,	NULL
myocarditis	NULL
was	NULL
significantly	NULL
inhibited	NULL
by	NULL
anti-Vy4	NULL
antibody	NULL
treatment	NULL
.	NULL

Anti-Vy1	NULL
antibody	NULL
treatment	NULL
exacerbated	NULL
disease	NULL
in	NULL
both	NULL
H3-	NULL
and	NULL
H310A1-infected	NULL
mice	NULL
.	NULL

Neither	NULL
antibody	NULL
induced	NULL
cardiac	NULL
lesions	NULL
by	NULL
itself	NULL
.	NULL

Hamster	NULL
IgG	NULL
,	NULL
used	NULL
as	NULL
an	NULL
isotype	NULL
control	NULL
,	NULL
has	NULL
little	NULL
effect	NULL
on	NULL
Vy1*	NULL
or	NULL
Vy4	NULL
*	NULL
cell	NULL
numbers	NULL
(	NULL
5.8	NULL
%	NULL
Hamster	NULL
IgG	NULL
Vy1*	NULL
and	NULL
3.1	NULL
%	NULL
cells	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

However	NULL
,	NULL
anti-Vy1	NULL
antibody	NULL
reduced	NULL
Vy1	NULL
*	NULL
cells	NULL
by	NULL
80	NULL
%	NULL
and	NULL
anti-Vy4	NULL
antibody	NULL
reduced	NULL
Vy4*	NULL
cells	NULL
by	NULL
60	NULL
to	NULL
70	NULL
%	NULL
(	NULL
Table	NULL
3	NULL
;	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
cells	NULL
remaining	NULL
were	NULL
only	NULL
weakly	NULL
positive	NULL
for	NULL
TcR	NULL
expression	NULL
.	NULL

In	NULL
the	NULL
same	NULL
mice	NULL
,	NULL
we	NULL
examined	NULL
splenic	NULL
CD4	NULL
*	NULL
cells	NULL
for	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
production	NULL
by	NULL
intracellular	NULL
cytokine	NULL
Anti	NULL
1000	NULL
>	NULL
1Le0e	NULL
&	NULL
1	NULL
1000	NULL
&	NULL
A	NULL
Anti-Vy1	NULL
@	NULL
7.0|	NULL
L1	NULL
}	NULL
®	NULL
grs|	NULL
1s	NULL
|	NULL
7	NULL
«	NULL
1080	NULL
1000	NULL
to	NULL
t	NULL
1000	NULL
>	NULL
‘	NULL
*	NULL
&	NULL
1	NULL
1900	NULL
«	NULL
1	NULL
&	NULL
4	NULL
&	NULL
®	NULL
10.7	NULL
]	NULL
2.7	NULL
vi	NULL
$	NULL
5.7	NULL
)	NULL
0.9	NULL
1	NULL
1	NULL
}	NULL
k	NULL
al	NULL
I	NULL
.	NULL

Former	NULL
T	NULL
CHIT	NULL
*	NULL
T	NULL
TOPTIME	NULL
T	NULL
DHI	NULL
1008	NULL
-	NULL
&	NULL
1	NULL
10600	NULL
Vy4	NULL
Jp	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Flow	NULL
analysis	NULL
of	NULL
splenocytes	NULL
expressing	NULL
the	NULL
y8	NULL
,	NULL
Vy1	NULL
,	NULL
and	NULL
Vy4	NULL
TeRs	NULL
.	NULL

BALB/c	NULL
mice	NULL
were	NULL
treated	NULL
with	NULL
300	NULL
ug	NULL
of	NULL
monoclonal	NULL
antibody	NULL
to	NULL
Vy1	NULL
or	NULL
Vy4	NULL
i.v	NULL
.	NULL

through	NULL
the	NULL
tail	NULL
vein	NULL
3	NULL
days	NULL
before	NULL
i.p	NULL
.	NULL

injection	NULL
of	NULL
10*	NULL
PFU	NULL
of	NULL
CVB3	NULL
.	NULL

Control	NULL
mice	NULL
were	NULL
given	NULL
300	NULL
ug	NULL
of	NULL
purified	NULL
hamster	NULL
IgG	NULL
.	NULL

Animals	NULL
were	NULL
killed	NULL
7	NULL
days	NULL
after	NULL
infection	NULL
.	NULL

Spleens	NULL
were	NULL
removed	NULL
,	NULL
and	NULL
the	NULL
lymphoid	NULL
cell	NULL
population	NULL
was	NULL
isolated	NULL
.	NULL

Aliquots	NULL
of	NULL
the	NULL
spleen	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
FITC-conjugated	NULL
anti-y8	NULL
and	NULL
either	NULL
biotinylated	NULL
hamster	NULL
anti-Vy1	NULL
or	NULL
anti-Vy4	NULL
and	NULL
PE-conjugated	NULL
streptavidin	NULL
to	NULL
indicate	NULL
Vy1*	NULL
and	NULL
Vy4~*	NULL
cell	NULL
subpopulations	NULL
.	NULL

Numbers	NULL
in	NULL
upper	NULL
right-hand	NULL
corner	NULL
indicate	NULL
percentages	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
quadrants	NULL
.	NULL

Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
TABLE	NULL
3	NULL
.	NULL

Antibody-mediated	NULL
depletion	NULL
of	NULL
Vy-cell	NULL
subsets	NULL
in	NULL
vivo	NULL
``	NULL
%	NULL
of	NULL
total	NULL
splenotypes	NULL
staining	NULL
positively	NULL
for	NULL
both	NULL
:	NULL
Virus	NULL
Treatment	NULL
y8	NULL
and	NULL
y8	NULL
and	NULL
_	NULL
CD4	NULL
and	NULL
CD4	NULL
and	NULL
Vy1	NULL
Vy4	NULL
IFN-y	NULL
IL-4	NULL
H3	NULL
Hamster	NULL
IgG	NULL
(	NULL
200	NULL
ug	NULL
)	NULL
3.5	NULL
11.6	NULL
3.8	NULL
+	NULL
1.2	NULL
51+1.1	NULL
0.2+0.2	NULL
0.8	NULL
£	NULL
0.3	NULL
%	NULL
4.5	NULL
+14	NULL
5.0	NULL
*	NULL
1.8	NULL
1.5	NULL
+0.3	NULL
«	NULL
8.3	NULL
+	NULL
1.6*	NULL
1.4	NULL
+	NULL
0.9*	NULL
2.2	NULL
+	NULL
0.6	NULL
%	NULL
0.5	NULL
+	NULL
0.5	NULL
Anti-Vy1	NULL
(	NULL
200	NULL
pg	NULL
)	NULL
Anti-Vy4	NULL
(	NULL
200	NULL
pg	NULL
)	NULL
43	NULL
£15	NULL
21	NULL
%	NULL
05	NULL
3.0	NULL
#	NULL
1.2	NULL
1405	NULL
0.5	NULL
+	NULL
0.4*	NULL
5.9	NULL
+	NULL
1.5	NULL
%	NULL
9.1	NULL
+	NULL
1.6	NULL
%	NULL
0.4	NULL
+	NULL
0.1	NULL
«	NULL
4.17	NULL
0.6	NULL
+	NULL
0.3	NULL
%	NULL
2.5	NULL
£	NULL
1.3	NULL
22+0.9	NULL
H310A1	NULL
Hamster	NULL
IgG	NULL
Anti-Vy1	NULL
Anti-Vy4	NULL
*	NULL
*	NULL
,	NULL
value	NULL
different	NULL
than	NULL
that	NULL
for	NULL
mice	NULL
treated	NULL
with	NULL
hamster	NULL
IgG	NULL
at	NULL
a	NULL
P	NULL
of	NULL
0.05.	NULL
staining	NULL
.	NULL

Figure	NULL
6	NULL
gives	NULL
representative	NULL
flow	NULL
diagrams	NULL
from	NULL
a	NULL
single	NULL
H3-infected	NULL
mouse	NULL
in	NULL
each	NULL
treatment	NULL
group	NULL
.	NULL

Table	NULL
3	NULL
summarizes	NULL
these	NULL
data	NULL
for	NULL
all	NULL
animals	NULL
infected	NULL
with	NULL
either	NULL
H3	NULL
or	NULL
H310A1	NULL
virus	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
found	NULL
that	NULL
anti-Vy4	NULL
treatment	NULL
slightly	NULL
reduced	NULL
both	NULL
CD4*	NULL
IFN-y*	NULL
(	NULL
Th1	NULL
)	NULL
and	NULL
non-CD4*	NULL
IFN-y*	NULL
cells	NULL
but	NULL
that	NULL
it	NULL
substantially	NULL
increased	NULL
CD4	NULL
*	NULL
IL-4*	NULL
and	NULL
non-CD4*	NULL
IL-4*	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
anti-Vy1	NULL
antibody	NULL
treatment	NULL
of	NULL
H310A1-infected	NULL
mice	NULL
slightly	NULL
increased	NULL
IFN-y*	NULL
and	NULL
reduced	NULL
IL-4	NULL
*	NULL
cells	NULL
.	NULL

Hamster	NULL
IgG	NULL
Anti-Vy4	NULL
y8*	NULL
T	NULL
CELLS	NULL
IN	NULL
MYOCARDITIS	NULL
-	NULL
5865	NULL
Adoptive	NULL
transfer	NULL
of	NULL
Vy1*	NULL
and	NULL
Vy4*	NULL
cells	NULL
from	NULL
BALB/c	NULL
Statd4	NULL
and	NULL
BALB/c	NULL
Statéko	NULL
mice	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
cytokine	NULL
made	NULL
by	NULL
the	NULL
y8	NULL
*-T-cell	NULL
subset	NULL
is	NULL
primarily	NULL
responsible	NULL
for	NULL
its	NULL
effect	NULL
on	NULL
CD4	NULL
*	NULL
-cell	NULL
responses	NULL
and	NULL
myocarditis	NULL
susceptibility	NULL
,	NULL
BALB/c	NULL
Stat4ko	NULL
and	NULL
BALB/c	NULL
Stat6	NULL
mice	NULL
were	NULL
infected	NULL
with	NULL
H3	NULL
virus	NULL
and	NULL
,	NULL
5	NULL
days	NULL
later	NULL
,	NULL
enriched	NULL
populations	NULL
of	NULL
Vy1	NULL
~*	NULL
and	NULL
Vy4*	NULL
cells	NULL
were	NULL
isolated	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

Figure	NULL
7	NULL
shows	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
expression	NULL
in	NULL
the	NULL
subpopulation	NULL
by	NULL
intracellular	NULL
cytokine	NULL
staining	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
both	NULL
Vy1	NULL
*	NULL
and	NULL
Vy4	NULL
*	NULL
cells	NULL
from	NULL
Statéko	NULL
mice	NULL
showed	NULL
predominant	NULL
IFN-y	NULL
but	NULL
minimal	NULL
IL-4	NULL
expression	NULL
.	NULL

Vy4	NULL
*	NULL
cells	NULL
consistently	NULL
stained	NULL
more	NULL
strongly	NULL
for	NULL
IFN-y	NULL
than	NULL
did	NULL
Vy1~*	NULL
cells	NULL
from	NULL
these	NULL
animals	NULL
.	NULL

Similarly	NULL
,	NULL
while	NULL
both	NULL
Vy1	NULL
*	NULL
and	NULL
Vy4	NULL
*	NULL
cells	NULL
from	NULL
Stat4ko	NULL
mice	NULL
stained	NULL
positively	NULL
for	NULL
IL-4	NULL
,	NULL
Vy4	NULL
*	NULL
cells	NULL
from	NULL
Statdko	NULL
mice	NULL
also	NULL
showed	NULL
some	NULL
residual	NULL
IFN-y	NULL
expression	NULL
,	NULL
compared	NULL
to	NULL
results	NULL
with	NULL
the	NULL
Vy1*	NULL
subpopulation	NULL
.	NULL

Wild-type	NULL
BALB/c	NULL
mice	NULL
were	NULL
infected	NULL
with	NULL
H3	NULL
virus	NULL
and	NULL
3	NULL
days	NULL
later	NULL
received	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
from	NULL
the	NULL
Vy	NULL
subsets	NULL
i.v	NULL
.	NULL

Table	NULL
4	NULL
shows	NULL
the	NULL
levels	NULL
of	NULL
myocarditis	NULL
and	NULL
percentages	NULL
of	NULL
CD4*	NULL
Th1	NULL
and	NULL
Th2	NULL
cells	NULL
in	NULL
recipient	NULL
animals	NULL
.	NULL

Vy1	NULL
*	NULL
cells	NULL
from	NULL
Stat4ko	NULL
(	NULL
IFN-y-deficient	NULL
)	NULL
mice	NULL
were	NULL
strongly	NULL
suppressive	NULL
for	NULL
both	NULL
myocarditis	NULL
and	NULL
CD4	NULL
*-Th1-cell	NULL
responses	NULL
.	NULL

Somewhat	NULL
surprisingly	NULL
,	NULL
Vy4*	NULL
cells	NULL
from	NULL
Statdko	NULL
mice	NULL
were	NULL
not	NULL
suppressive	NULL
,	NULL
even	NULL
Anti-Vy1l	NULL
o	NULL
&	NULL
-	NULL
a	NULL
¥	NULL
-	NULL
S3	NULL
20.5	NULL
;	NULL
5.9	NULL
o	NULL
17.4	NULL
|	NULL
23	NULL
¢	NULL
o	NULL
14.3	NULL
|	NULL
4.2	NULL
41	NULL
i	NULL
-	NULL
75.1	NULL
|	NULL
5.9	NULL
s	NULL
77.2	NULL
)	NULL
4.7	NULL
2.0	NULL
'	NULL
‘	NULL
-A	NULL
A	NULL
2g	NULL
.	NULL

-	NULL
a	NULL
*	NULL
*	NULL
Thimm	NULL
Tom	NULL
*	NULL
&	NULL
1	NULL
1000	NULL
18000	NULL
10909	NULL
®	NULL
o	NULL
s	NULL
®	NULL
19.6	NULL
|	NULL
0.3	NULL
°	NULL
D	NULL
17.6	NULL
|	NULL
1.6	NULL
&	NULL
16.3	NULL
|	NULL
0.8	NULL
°	NULL
he	NULL
.	NULL

a	NULL
w	NULL
79.4	NULL
|	NULL
0.7	NULL
77.8	NULL
|	NULL
3	NULL
.	NULL

82.3	NULL
|	NULL
0.3	NULL
<	NULL
U	NULL
-	NULL
frt	NULL
Ent	NULL
T1	NULL
*	NULL
t	NULL
TPH	NULL
__	NULL
*	NULL
-T	NULL
7mm	NULL
«	NULL
1	NULL
1000	NULL
24	NULL
iran	NULL
&	NULL
1	NULL
1000	NULL
IL-4	NULL
>	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Flow	NULL
analysis	NULL
of	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
intracellular	NULL
staining	NULL
in	NULL
the	NULL
CD4*	NULL
cell	NULL
population	NULL
of	NULL
antibody-treated	NULL
H3	NULL
virus-infected	NULL
mice	NULL
.	NULL

Splenocytes	NULL
from	NULL
control	NULL
and	NULL
antibody-treated	NULL
mice	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

4	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
,	NULL
ionomycin	NULL
,	NULL
and	NULL
brefeldin	NULL
A	NULL
for	NULL
4	NULL
h	NULL
;	NULL
stained	NULL
for	NULL
CD4	NULL
surface	NULL
marker	NULL
;	NULL
fixed	NULL
;	NULL
permeablized	NULL
;	NULL
stained	NULL
intracellularly	NULL
for	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
;	NULL
and	NULL
evaluated	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Numbers	NULL
in	NULL
the	NULL
upper	NULL
right-hand	NULL
corner	NULL
indicate	NULL
percentages	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
quadrants	NULL
.	NULL

5866	NULL
HUBER	NULL
ET	NULL
AL	NULL
.	NULL

ﬁ	NULL
1030	NULL
«	NULL
ann	NULL
1000	NULL
g	NULL
{	NULL
Uu	NULL
f	NULL
r	NULL
numg	NULL
(	NULL
rvcuia	NULL
6	NULL
21	NULL
1000	NULL
24	NULL
-	NULL
1	NULL
1000	NULL
o	NULL
3	NULL
&	NULL
x	NULL
a	NULL
j	NULL
&	NULL
a	NULL
4	NULL
o	NULL
w-A7	NULL
3	NULL
3	NULL
&	NULL
~-	NULL
a=	NULL
Z	NULL
6	NULL
|	NULL
&	NULL
3	NULL
LLt	NULL
«	NULL
>	NULL
-	NULL
P4—	NULL
Looame	NULL
,	NULL
*	NULL
*	NULL
i	NULL
J.	NULL
Virou	NULL
.	NULL

Vy1	NULL
Stat	NULL
6k0o	NULL
1009	NULL
Vy4	NULL
Stat	NULL
6ko	NULL
Vy1	NULL
Stat	NULL
4ko	NULL
Vy4	NULL
Stat	NULL
4ko	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Flow	NULL
analysis	NULL
of	NULL
intracellular	NULL
cytokine	NULL
staining	NULL
of	NULL
enriched	NULL
Vy1*	NULL
and	NULL
Vy4	NULL
*	NULL
cells	NULL
from	NULL
BALB/c	NULL
Statéko	NULL
and	NULL
BALB/c	NULL
Statd4ko	NULL
mice	NULL
.	NULL

Mice	NULL
were	NULL
infected	NULL
with	NULL
H3	NULL
virus	NULL
and	NULL
killed	NULL
5	NULL
days	NULL
later	NULL
.	NULL

Spleens	NULL
were	NULL
removed	NULL
,	NULL
and	NULL
enriched	NULL
populations	NULL
of	NULL
Vy	NULL
subpopulations	NULL
were	NULL
isolated	NULL
as	NULL
described	NULL
both	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
and	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Aliquots	NULL
of	NULL
the	NULL
cell	NULL
populations	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
,	NULL
ionomycin	NULL
,	NULL
and	NULL
brefeldin	NULL
A	NULL
;	NULL
surface	NULL
stained	NULL
for	NULL
the	NULL
FITC-conjugated	NULL
y8	NULL
TeR	NULL
;	NULL
and	NULL
intracellularly	NULL
stained	NULL
with	NULL
PE-conjugated	NULL
anti-IL-4	NULL
and	NULL
biotinylated	NULL
anti-IFN-y	NULL
and	NULL
then	NULL
with	NULL
Red	NULL
613	NULL
streptavidin	NULL
.	NULL

though	NULL
these	NULL
cells	NULL
express	NULL
IL-4	NULL
.	NULL

Similarly	NULL
,	NULL
Vy1*	NULL
cells	NULL
from	NULL
Statéko	NULL
(	NULL
IL-4	NULL
deficient	NULL
)	NULL
mice	NULL
had	NULL
no	NULL
significant	NULL
effect	NULL
on	NULL
either	NULL
myocarditis	NULL
or	NULL
CD4	NULL
*	NULL
-cell	NULL
responses	NULL
,	NULL
yet	NULL
Vy4	NULL
*	NULL
cells	NULL
from	NULL
these	NULL
donors	NULL
substantially	NULL
enhanced	NULL
both	NULL
disease	NULL
and	NULL
Th1	NULL
cell	NULL
bias	NULL
.	NULL

DISCUSSION	NULL
We	NULL
had	NULL
previously	NULL
found	NULL
that	NULL
H3	NULL
virus	NULL
infection	NULL
of	NULL
C57BL/6	NULL
mice	NULL
activates	NULL
Vy1	NULL
*	NULL
cells	NULL
,	NULL
which	NULL
suppress	NULL
myocarditis	NULL
,	NULL
but	NULL
that	NULL
infection	NULL
of	NULL
Bl.Tg.Ea	NULL
mice	NULL
activates	NULL
*	NULL
cells	NULL
,	NULL
which	NULL
promote	NULL
myocarditis	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Since	NULL
Vy4	NULL
*	NULL
cells	NULL
are	NULL
4-	NULL
to	NULL
10-fold	NULL
more	NULL
abundant	NULL
in	NULL
Bl.Tg.Ea	NULL
«	NULL
than	NULL
in	NULL
C57BL/6	NULL
animals	NULL
,	NULL
possibly	NULL
because	NULL
the	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
IE	NULL
antigen	NULL
in	NULL
Bl.Tg.Ea	NULL
mice	NULL
influences	NULL
y8	NULL
*	NULL
cell	NULL
subset	NULL
generation	NULL
during	NULL
T-cell	NULL
on-togeny	NULL
,	NULL
activation	NULL
of	NULL
distinct	NULL
Vy	NULL
*	NULL
cell	NULL
subsets	NULL
in	NULL
the	NULL
C57BL/6	NULL
and	NULL
Bl.Tg.Ea	NULL
animals	NULL
might	NULL
simply	NULL
reflect	NULL
virus	NULL
activation	NULL
of	NULL
whatever	NULL
y8	NULL
*	NULL
cells	NULL
are	NULL
present	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
results	NULL
presented	NULL
in	NULL
this	NULL
paper	NULL
clearly	NULL
demonstrate	NULL
that	NULL
myocarditic	NULL
and	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
TABLE	NULL
4	NULL
.	NULL

Effect	NULL
of	NULL
cytokine	NULL
production	NULL
by	NULL
y8*	NULL
T-cell	NULL
subsets	NULL
on	NULL
CVB3-induced	NULL
myocarditis*	NULL
Subset	NULL
%	NULL
of	NULL
myocardium	NULL
%	NULL
of	NULL
CD4	NULL
%	NULL
of	NULL
CD4	NULL
transferred	NULL
inflamed	NULL
IFN-y*	NULL
cells	NULL
IL-4*	NULL
cells	NULL
None	NULL
9.3	NULL
+	NULL
1.6	NULL
12.6	NULL
+	NULL
2.7	NULL
3.3	NULL
+	NULL
0.9	NULL
Vy1	NULL
Statéko	NULL
7.2	NULL
*	NULL
24	NULL
9.9	NULL
£	NULL
2.5	NULL
2.5	NULL
+	NULL
0.7	NULL
Vy1	NULL
Statdko	NULL
2.0	NULL
+	NULL
0.8	NULL
#	NULL
4.3	NULL
£	NULL
1.5	NULL
%	NULL
7.0	NULL
+	NULL
1.6*	NULL
Vy4	NULL
Statéko	NULL
15.6	NULL
+	NULL
1.2	NULL
«	NULL
22.4	NULL
+	NULL
4.1	NULL
%	NULL
1.9	NULL
+	NULL
#	NULL
1.5	NULL
Vy4	NULL
Statdko	NULL
10.4	NULL
+	NULL
2.8	NULL
10.2	NULL
+	NULL
1.9	NULL
4.8	NULL
+	NULL
2.1	NULL
*	NULL
Donor	NULL
mice	NULL
were	NULL
infected	NULL
with	NULL
10	NULL
``	NULL
PFU	NULL
of	NULL
H3	NULL
in	NULL
0.5	NULL
ml	NULL
of	NULL
PBS	NULL
.	NULL

Spleens	NULL
were	NULL
removed	NULL
5	NULL
days	NULL
later	NULL
.	NULL

aB	NULL
*	NULL
,	NULL
MAC3*	NULL
,	NULL
and	NULL
IA®*	NULL
cells	NULL
were	NULL
depleted	NULL
using	NULL
antibody	NULL
and	NULL
magnetic	NULL
particles	NULL
.	NULL

The	NULL
residual	NULL
cells	NULL
were	NULL
cultured	NULL
on	NULL
anti-Vy1-	NULL
or	NULL
anti-Vy4-coated	NULL
plates	NULL
for	NULL
3	NULL
days	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
retrieved	NULL
,	NULL
centrifuged	NULL
on	NULL
Histopaque	NULL
,	NULL
resuspended	NULL
in	NULL
PBS	NULL
to	NULL
2.5	NULL
X	NULL
10°	NULL
cells/ml	NULL
,	NULL
and	NULL
injected	NULL
i.v	NULL
.	NULL

through	NULL
the	NULL
tail	NULL
vein	NULL
(	NULL
0.2	NULL
ml	NULL
or	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
into	NULL
BALB/c	NULL
recipients	NULL
infected	NULL
3	NULL
days	NULL
earlier	NULL
with	NULL
H3	NULL
virus	NULL
.	NULL

Recipients	NULL
were	NULL
killed	NULL
4	NULL
days	NULL
after	NULL
receiving	NULL
Vy-enriched	NULL
populations	NULL
.	NULL

Hearts	NULL
of	NULL
recipients	NULL
were	NULL
evaluated	NULL
for	NULL
myocardial	NULL
inflammation	NULL
.	NULL

Spleen	NULL
lymphocytes	NULL
were	NULL
evaluated	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
for	NULL
percentages	NULL
of	NULL
CD4	NULL
cells	NULL
staining	NULL
intracellularly	NULL
for	NULL
IFN-y	NULL
or	NULL
IL-4	NULL
.	NULL

Results	NULL
are	NULL
means	NULL
+	NULL
SEM	NULL
of	NULL
results	NULL
with	NULL
four	NULL
or	NULL
more	NULL
mice	NULL
per	NULL
group	NULL
.	NULL

*	NULL
,	NULL
value	NULL
significantly	NULL
different	NULL
than	NULL
that	NULL
for	NULL
H3-infected	NULL
BALB/c	NULL
mice	NULL
not	NULL
given	NULL
V	NULL
>	NULL
cells	NULL
.	NULL

nonmyocarditic	NULL
CVB3s	NULL
selectively	NULL
activate	NULL
different	NULL
y8	NULL
``	NULL
subsets	NULL
associated	NULL
with	NULL
modulating	NULL
the	NULL
CD4	NULL
*-Th-cell	NULL
phenotype	NULL
.	NULL

The	NULL
Thli-cell-Th2-cell	NULL
dichotomy	NULL
in	NULL
disease	NULL
susceptibility	NULL
and	NULL
resistance	NULL
is	NULL
well	NULL
recognized	NULL
(	NULL
8	NULL
,	NULL
11	NULL
,	NULL
19	NULL
,	NULL
24	NULL
,	NULL
32	NULL
,	NULL
37	NULL
)	NULL
.	NULL

In	NULL
those	NULL
diseases	NULL
which	NULL
are	NULL
dependent	NULL
on	NULL
proinflammatory	NULL
cytokines	NULL
such	NULL
as	NULL
IL-1	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
,	NULL
Thl-cell	NULL
responses	NULL
are	NULL
often	NULL
pathogenic	NULL
while	NULL
Th2-cell	NULL
responses	NULL
are	NULL
protective	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
diseases	NULL
requiring	NULL
T-cell-dependent	NULL
B-cell	NULL
responses	NULL
,	NULL
such	NULL
as	NULL
IgE-dependent	NULL
allergies	NULL
,	NULL
Th2	NULL
cells	NULL
correlate	NULL
with	NULL
disease	NULL
whereas	NULL
Th1	NULL
cells	NULL
can	NULL
be	NULL
protective	NULL
.	NULL

In	NULL
CVB3-induced	NULL
myocarditis	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
and	NULL
IL-18	NULL
are	NULL
crucial	NULL
to	NULL
myocarditis	NULL
susceptibility	NULL
(	NULL
25	NULL
)	NULL
but	NULL
T-cell-dependent	NULL
responses	NULL
are	NULL
not	NULL
required	NULL
for	NULL
virus	NULL
clearance	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
Th1-cell	NULL
responses	NULL
are	NULL
predicted	NULL
to	NULL
be	NULL
pathogenic	NULL
in	NULL
this	NULL
disease	NULL
.	NULL

y8	NULL
*	NULL
cells	NULL
clearly	NULL
can	NULL
modulate	NULL
Th1	NULL
and	NULL
Th2	NULL
responses	NULL
either	NULL
directly	NULL
or	NULL
indirectly	NULL
,	NULL
as	NULL
has	NULL
been	NULL
shown	NULL
by	NULL
various	NULL
published	NULL
reports	NULL
.	NULL

The	NULL
assumed	NULL
mechanism	NULL
for	NULL
this	NULL
modulation	NULL
is	NULL
through	NULL
cytokine	NULL
production	NULL
by	NULL
the	NULL
y8	NULL
*	NULL
cells	NULL
,	NULL
which	NULL
provide	NULL
the	NULL
appropriate	NULL
environment	NULL
to	NULL
influence	NULL
CD4	NULL
*	NULL
-cell	NULL
differentiation	NULL
(	NULL
7	NULL
,	NULL
8	NULL
,	NULL
26	NULL
,	NULL
44	NULL
)	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
y8	NULL
*	NULL
cells	NULL
should	NULL
be	NULL
quickly	NULL
activated	NULL
in	NULL
peripheral	NULL
lymphoid	NULL
tissues	NULL
and	NULL
rapidly	NULL
accumulate	NULL
at	NULL
local	NULL
inflammatory	NULL
sites	NULL
in	NULL
order	NULL
to	NULL
maximally	NULL
influence	NULL
the	NULL
developing	NULL
antigen-specific	NULL
immune	NULL
response	NULL
.	NULL

y8	NULL
~	NULL
T	NULL
cells	NULL
are	NULL
excellent	NULL
candidates	NULL
for	NULL
the	NULL
early	NULL
cytokine	NULL
response	NULL
because	NULL
these	NULL
cells	NULL
can	NULL
respond	NULL
to	NULL
broadly	NULL
distributed	NULL
antigens	NULL
in	NULL
damaged	NULL
tissues	NULL
and	NULL
microbes	NULL
,	NULL
such	NULL
as	NULL
heat	NULL
shock	NULL
proteins	NULL
(	NULL
2	NULL
)	NULL
,	NULL
and	NULL
do	NULL
not	NULL
require	NULL
classical	NULL
antigen	NULL
processing	NULL
and	NULL
MHC-restricted	NULL
presentation	NULL
.	NULL

Moreover	NULL
,	NULL
y8	NULL
*	NULL
T	NULL
cells	NULL
have	NULL
a	NULL
memory	NULL
phenotype	NULL
in	NULL
the	NULL
periphery	NULL
,	NULL
suggestive	NULL
of	NULL
prior	NULL
antigen	NULL
activation	NULL
,	NULL
and	NULL
the	NULL
potential	NULL
for	NULL
rapid	NULL
expansion	NULL
(	NULL
40	NULL
,	NULL
42	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
communication	NULL
,	NULL
we	NULL
demonstrate	NULL
that	NULL
few	NULL
y8*	NULL
T	NULL
cells	NULL
from	NULL
uninfected	NULL
mice	NULL
express	NULL
cytokines	NULL
by	NULL
intracellular	NULL
cytokine	NULL
staining	NULL
but	NULL
that	NULL
many	NULL
y8	NULL
*	NULL
T	NULL
cells	NULL
from	NULL
H3-infected	NULL
animals	NULL
express	NULL
high	NULL
levels	NULL
of	NULL
IFN-y	NULL
.	NULL

In	NULL
these	NULL
animals	NULL
,	NULL
the	NULL
stronger	NULL
IFN-y	NULL
expression	NULL
in	NULL
Vy4~*	NULL
cells	NULL
than	NULL
that	NULL
in	NULL
Vy1~*	NULL
cells	NULL
conforms	NULL
to	NULL
a	NULL
predicted	NULL
superiority	NULL
of	NULL
the	NULL
Vy4*	NULL
population	NULL
in	NULL
Th1-cell	NULL
modulation	NULL
.	NULL

Thus	NULL
,	NULL
based	NULL
on	NULL
the	NULL
cytokine	NULL
pat-terns	NULL
,	NULL
depletion	NULL
of	NULL
Vy4~*	NULL
cells	NULL
in	NULL
H3-infected	NULL
animals	NULL
is	NULL
expected	NULL
to	NULL
reduce	NULL
Th1-cell	NULL
responses	NULL
,	NULL
as	NULL
was	NULL
seen	NULL
in	NULL
this	NULL
study	NULL
.	NULL

There	NULL
are	NULL
certain	NULL
discrepancies	NULL
in	NULL
the	NULL
data	NULL
,	NULL
however	NULL
.	NULL

Anti-Vy1	NULL
y8*	NULL
T	NULL
CELLS	NULL
IN	NULL
MYOCARDITIS	NULL
-	NULL
5867	NULL
antibody	NULL
treatment	NULL
of	NULL
H3	NULL
virus-infected	NULL
mice	NULL
results	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
CD4	NULL
*	NULL
IL-4~*	NULL
cells	NULL
from	NULL
0.2	NULL
to	NULL
1.5	NULL
%	NULL
(	NULL
Table	NULL
3	NULL
)	NULL
.	NULL

If	NULL
Vy1	NULL
*	NULL
cells	NULL
uniformly	NULL
promote	NULL
CD4	NULL
*-Th2-cell	NULL
responses	NULL
,	NULL
this	NULL
result	NULL
is	NULL
perplexing	NULL
.	NULL

We	NULL
do	NULL
not	NULL
have	NULL
an	NULL
explanation	NULL
for	NULL
this	NULL
finding	NULL
,	NULL
but	NULL
as	NULL
discussed	NULL
below	NULL
,	NULL
antibody	NULL
treatment	NULL
might	NULL
stimulate	NULL
as	NULL
well	NULL
as	NULL
eliminate	NULL
specific	NULL
cell	NULL
populations	NULL
.	NULL

Activating	NULL
Vy1*	NULL
cells	NULL
prior	NULL
to	NULL
their	NULL
elimination	NULL
might	NULL
simultaneously	NULL
cause	NULL
increases	NULL
in	NULL
CD4*	NULL
Th1	NULL
cells	NULL
(	NULL
through	NULL
elimination	NULL
of	NULL
Vy1	NULL
*	NULL
cells	NULL
)	NULL
and	NULL
increases	NULL
in	NULL
CD4*	NULL
Th2+*	NULL
cells	NULL
(	NULL
through	NULL
activation	NULL
of	NULL
Vy1	NULL
*	NULL
cells	NULL
prior	NULL
to	NULL
their	NULL
elimination	NULL
and	NULL
the	NULL
release	NULL
of	NULL
Th2-promoting	NULL
factors	NULL
)	NULL
.	NULL

The	NULL
results	NULL
are	NULL
also	NULL
unclear	NULL
for	NULL
H310A1-infected	NULL
mice	NULL
.	NULL

Here	NULL
,	NULL
anti-	NULL
Vy1	NULL
antibody	NULL
treatment	NULL
enhanced	NULL
myocarditis	NULL
but	NULL
the	NULL
IFN-y	NULL
staining	NULL
of	NULL
the	NULL
Vy4	NULL
*	NULL
cells	NULL
in	NULL
these	NULL
animals	NULL
was	NULL
modest	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
is	NULL
not	NULL
clear	NULL
why	NULL
depletion	NULL
of	NULL
the	NULL
Vy1*	NULL
cells	NULL
promoted	NULL
CD4	NULL
*-Th1-cell	NULL
responses	NULL
based	NULL
solely	NULL
on	NULL
the	NULL
cytokine	NULL
data	NULL
.	NULL

One	NULL
possibility	NULL
is	NULL
that	NULL
other	NULL
cytokines	NULL
differ	NULL
in	NULL
their	NULL
levels	NULL
of	NULL
Vy1*	NULL
and	NULL
Vy4	NULL
*	NULL
cells	NULL
,	NULL
which	NULL
may	NULL
be	NULL
potential	NULL
regulators	NULL
of	NULL
the	NULL
CD4	NULL
*	NULL
response	NULL
,	NULL
either	NULL
through	NULL
direct	NULL
action	NULL
on	NULL
the	NULL
CD4	NULL
*-cell	NULL
population	NULL
or	NULL
by	NULL
influencing	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
such	NULL
as	NULL
macrophages	NULL
,	NULL
which	NULL
subsequently	NULL
alter	NULL
Th-cell	NULL
development	NULL
(	NULL
23	NULL
)	NULL
.	NULL

y8	NULL
*	NULL
T	NULL
cells	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
make	NULL
IL-13	NULL
,	NULL
a	NULL
cytokine	NULL
known	NULL
to	NULL
promote	NULL
Th2-dependent	NULL
responses	NULL
such	NULL
as	NULL
IgE	NULL
production	NULL
(	NULL
12	NULL
,	NULL
30	NULL
)	NULL
.	NULL

This	NULL
would	NULL
enable	NULL
Vy1	NULL
*	NULL
T	NULL
cells	NULL
to	NULL
promote	NULL
Th2-cell	NULL
responses	NULL
even	NULL
if	NULL
they	NULL
make	NULL
little	NULL
if	NULL
any	NULL
IL-4	NULL
.	NULL

Experiments	NULL
using	NULL
antibody-induced	NULL
depletion	NULL
of	NULL
y8	NULL
*	NULL
cells	NULL
in	NULL
vivo	NULL
have	NULL
potential	NULL
problems	NULL
,	NULL
even	NULL
though	NULL
it	NULL
has	NULL
been	NULL
used	NULL
by	NULL
various	NULL
investigators	NULL
for	NULL
Vy-subset	NULL
depletion	NULL
(	NULL
31	NULL
,	NULL
34	NULL
)	NULL
.	NULL

Antibody	NULL
binding	NULL
to	NULL
the	NULL
TcR	NULL
might	NULL
activate	NULL
cells	NULL
to	NULL
release	NULL
cytokines	NULL
and	NULL
immunomodulate	NULL
«	NULL
B	NULL
*-T-cell	NULL
responses	NULL
,	NULL
prior	NULL
to	NULL
their	NULL
elimination	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
antibody	NULL
depletion	NULL
experiments	NULL
might	NULL
indicate	NULL
that	NULL
either	NULL
the	NULL
lack	NULL
of	NULL
or	NULL
the	NULL
activation	NULL
of	NULL
specific	NULL
subpopulations	NULL
resulted	NULL
in	NULL
the	NULL
observed	NULL
effects	NULL
.	NULL

Studies	NULL
by	NULL
R.	NULL
O'Brien	NULL
and	NULL
her	NULL
colleagues	NULL
indicate	NULL
that	NULL
treatment	NULL
of	NULL
mice	NULL
with	NULL
the	NULL
monoclonal	NULL
antibodies	NULL
causes	NULL
depletion	NULL
of	NULL
cells	NULL
within	NULL
24	NULL
h	NULL
and	NULL
remains	NULL
effective	NULL
for	NULL
2	NULL
weeks	NULL
.	NULL

Since	NULL
the	NULL
monoclonal	NULL
antibodies	NULL
in	NULL
this	NULL
study	NULL
were	NULL
given	NULL
3	NULL
days	NULL
prior	NULL
to	NULL
infection	NULL
,	NULL
presumably	NULL
any	NULL
cytokines	NULL
released	NULL
due	NULL
to	NULL
antibody-mediated	NULL
TeR	NULL
cross-linking	NULL
should	NULL
have	NULL
been	NULL
cleared	NULL
by	NULL
the	NULL
time	NULL
of	NULL
infection	NULL
.	NULL

Another	NULL
potential	NULL
problem	NULL
is	NULL
that	NULL
the	NULL
antibodies	NULL
did	NULL
not	NULL
totally	NULL
eliminate	NULL
the	NULL
relevant	NULL
cell	NULL
populations	NULL
,	NULL
and	NULL
although	NULL
it	NULL
is	NULL
quite	NULL
clear	NULL
that	NULL
most	NULL
Vy1	NULL
*	NULL
or	NULL
Vy4	NULL
~*	NULL
cells	NULL
had	NULL
been	NULL
eliminated	NULL
,	NULL
some	NULL
dull-staining	NULL
cells	NULL
remained	NULL
.	NULL

Whether	NULL
these	NULL
cells	NULL
can	NULL
affect	NULL
CD4	NULL
*	NULL
-cell	NULL
responses	NULL
is	NULL
not	NULL
known	NULL
.	NULL

It	NULL
is	NULL
also	NULL
not	NULL
clear	NULL
whether	NULL
the	NULL
residual	NULL
IFN-y*	NULL
cells	NULL
in	NULL
anti-Vy4	NULL
antibody-treated	NULL
mice	NULL
reflect	NULL
cells	NULL
resistant	NULL
to	NULL
y8	NULL
*	NULL
-T-cell	NULL
influence	NULL
or	NULL
whether	NULL
complete	NULL
elimination	NULL
of	NULL
the	NULL
Vy4~*	NULL
cells	NULL
would	NULL
have	NULL
more	NULL
effectively	NULL
reduced	NULL
the	NULL
number	NULL
of	NULL
IFN-y-producing	NULL
cells	NULL
.	NULL

Adoptive-transfer	NULL
experiments	NULL
using	NULL
enriched	NULL
populations	NULL
of	NULL
Vy1*	NULL
and	NULL
Vy4*	NULL
cells	NULL
were	NULL
done	NULL
to	NULL
complement	NULL
the	NULL
antibody	NULL
depletion	NULL
experiments	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
we	NULL
know	NULL
that	NULL
the	NULL
y8	NULL
*	NULL
subpopulations	NULL
are	NULL
strongly	NULL
activated	NULL
prior	NULL
to	NULL
injection	NULL
into	NULL
recipient	NULL
mice	NULL
,	NULL
and	NULL
effects	NULL
observed	NULL
in	NULL
the	NULL
recipient	NULL
should	NULL
reflect	NULL
the	NULL
direct	NULL
or	NULL
indirect	NULL
consequences	NULL
of	NULL
these	NULL
specific	NULL
Vy	NULL
subpopulations	NULL
.	NULL

To	NULL
clarify	NULL
whether	NULL
cytokines	NULL
made	NULL
by	NULL
y8	NULL
*	NULL
cells	NULL
exclusively	NULL
control	NULL
myocarditis	NULL
susceptibility	NULL
,	NULL
we	NULL
isolated	NULL
Vy1	NULL
*	NULL
and	NULL
Vy4~*	NULL
cells	NULL
from	NULL
BALB/c	NULL
transgenic	NULL
mice	NULL
lacking	NULL
either	NULL
the	NULL
Stat4	NULL
or	NULL
Stat6	NULL
transcription	NULL
factor	NULL
required	NULL
for	NULL
expression	NULL
of	NULL
IL-12	NULL
or	NULL
IL-4	NULL
,	NULL
respectively	NULL
(	NULL
3	NULL
,	NULL
29	NULL
)	NULL
.	NULL

Stat4ko	NULL
mice	NULL
are	NULL
strongly	NULL
5868	NULL
HUBER	NULL
ET	NULL
AL	NULL
.	NULL

biased	NULL
toward	NULL
a	NULL
Th2-cell	NULL
phenotype	NULL
because	NULL
of	NULL
the	NULL
lack	NULL
of	NULL
IL-12	NULL
needed	NULL
to	NULL
stimulate	NULL
IFN-y	NULL
responses	NULL
.	NULL

Both	NULL
Vy1*	NULL
and	NULL
Vy4*	NULL
cells	NULL
from	NULL
Stat4ko	NULL
mice	NULL
showed	NULL
substantial	NULL
IL-4	NULL
expression	NULL
by	NULL
intracellular	NULL
cytokine	NULL
staining	NULL
,	NULL
yet	NULL
only	NULL
the	NULL
Vy1*	NULL
subpopulation	NULL
suppressed	NULL
myocarditis	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
suppression	NULL
by	NULL
the	NULL
Vy4*	NULL
cells	NULL
might	NULL
result	NULL
from	NULL
residual	NULL
IFN-y	NULL
expression	NULL
in	NULL
this	NULL
population	NULL
.	NULL

A	NULL
study	NULL
by	NULL
Cai	NULL
et	NULL
al	NULL
.	NULL

(	NULL
3	NULL
)	NULL
also	NULL
found	NULL
residual	NULL
IFN-y	NULL
expression	NULL
in	NULL
Toxoplasma	NULL
gondii-infected	NULL
animals	NULL
,	NULL
indicating	NULL
an	NULL
IL-12-independent	NULL
pathway	NULL
for	NULL
IFN-y	NULL
expression	NULL
.	NULL

The	NULL
modest	NULL
IFN-y	NULL
expression	NULL
in	NULL
Vy4	NULL
*	NULL
cells	NULL
from	NULL
Stat4ko	NULL
mice	NULL
might	NULL
be	NULL
sufficient	NULL
to	NULL
negate	NULL
any	NULL
suppressive	NULL
activity	NULL
of	NULL
IL-4	NULL
on	NULL
CD4	NULL
*-cell	NULL
responses	NULL
.	NULL

However	NULL
,	NULL
this	NULL
study	NULL
might	NULL
also	NULL
indicate	NULL
that	NULL
the	NULL
cytokines	NULL
made	NULL
by	NULL
the	NULL
Vy	NULL
subpopulations	NULL
only	NULL
partially	NULL
explain	NULL
their	NULL
effects	NULL
on	NULL
CD4	NULL
*	NULL
responses	NULL
.	NULL

Vy1	NULL
*	NULL
cells	NULL
from	NULL
Statéko	NULL
mice	NULL
express	NULL
IFN-y	NULL
but	NULL
negligible	NULL
IL-4	NULL
.	NULL

These	NULL
cells	NULL
lose	NULL
their	NULL
ability	NULL
to	NULL
suppress	NULL
myocarditis	NULL
but	NULL
fail	NULL
to	NULL
aggravate	NULL
the	NULL
disease	NULL
,	NULL
as	NULL
is	NULL
seen	NULL
with	NULL
Vy4	NULL
*	NULL
cells	NULL
from	NULL
Statéko	NULL
animals	NULL
.	NULL

Again	NULL
,	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
IFN-y	NULL
responses	NULL
is	NULL
greater	NULL
in	NULL
the	NULL
Vy4*	NULL
than	NULL
in	NULL
the	NULL
Vy1~*	NULL
cell	NULL
population	NULL
.	NULL

The	NULL
relative	NULL
concentrations	NULL
of	NULL
IFN-y	NULL
and	NULL
IL-4	NULL
may	NULL
be	NULL
the	NULL
determining	NULL
factor	NULL
in	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
Th1-	NULL
or	NULL
Th2-cell	NULL
response	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
CD4	NULL
*	NULL
cells	NULL
are	NULL
not	NULL
the	NULL
only	NULL
splenocytes	NULL
making	NULL
IFN-y	NULL
or	NULL
IL-4	NULL
.	NULL

One	NULL
or	NULL
more	NULL
populations	NULL
of	NULL
non-CD4	NULL
*	NULL
cells	NULL
also	NULL
stain	NULL
intracellularly	NULL
for	NULL
these	NULL
cytokines	NULL
.	NULL

To	NULL
date	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
non-CD4	NULL
*	NULL
cytokine-positive	NULL
cell	NULL
population	NULL
(	NULL
s	NULL
)	NULL
correlates	NULL
with	NULL
the	NULL
CD4	NULL
*	NULL
-cell	NULL
response	NULL
.	NULL

That	NULL
is	NULL
,	NULL
treatment	NULL
of	NULL
H3-infected	NULL
mice	NULL
with	NULL
anti-	NULL
Vy4	NULL
antibody	NULL
reduces	NULL
not	NULL
only	NULL
the	NULL
percentage	NULL
of	NULL
CD4*	NULL
IFN-y	NULL
*	NULL
cells	NULL
but	NULL
also	NULL
that	NULL
of	NULL
these	NULL
non-CD4*	NULL
IFN-y*	NULL
cells	NULL
as	NULL
well	NULL
.	NULL

Many	NULL
of	NULL
these	NULL
cells	NULL
can	NULL
be	NULL
accounted	NULL
for	NULL
by	NULL
Vy4	NULL
*	NULL
cells	NULL
themselves	NULL
.	NULL

CD8	NULL
*	NULL
T	NULL
cells	NULL
can	NULL
not	NULL
be	NULL
shown	NULL
to	NULL
stain	NULL
for	NULL
cytokines	NULL
.	NULL

The	NULL
remaining	NULL
cells	NULL
besides	NULL
CD4*	NULL
and	NULL
y8	NULL
*	NULL
cells	NULL
might	NULL
be	NULL
natural	NULL
killer	NULL
(	NULL
NK	NULL
)	NULL
cells	NULL
which	NULL
are	NULL
often	NULL
cytokine	NULL
positive	NULL
(	NULL
39	NULL
)	NULL
.	NULL

If	NULL
NK	NULL
cells	NULL
are	NULL
present	NULL
in	NULL
the	NULL
cytokine-positive	NULL
population	NULL
,	NULL
then	NULL
y8	NULL
*	NULL
cells	NULL
might	NULL
be	NULL
able	NULL
to	NULL
affect	NULL
cytokine	NULL
responses	NULL
in	NULL
this	NULL
population	NULL
as	NULL
well	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
following	NULL
grants	NULL
and	NULL
institutional	NULL
support	NULL
:	NULL
grant	NULL
RO1	NULL
HL58583	NULL
(	NULL
S.	NULL
A.	NULL
Huber	NULL
)	NULL
;	NULL
grant	NULL
RO1	NULL
AI44920	NULL
(	NULL
from	NULL
the	NULL
Rocky	NULL
Mountain	NULL
Chapter	NULL
of	NULL
the	NULL
Arthritis	NULL
Foundation	NULL
)	NULL
and	NULL
EPA	NULL
project	NULL
grant	NULL
R825793	NULL
(	NULL
R.	NULL
L.	NULL
O'Brien	NULL
)	NULL
;	NULL
and	NULL
NIH	NULL
grant	NULL
RO1	NULL
AI40611	NULL
and	NULL
EPA	NULL
project	NULL
grant	NULL
R825793	NULL
(	NULL
W.	NULL
K.	NULL
Born	NULL
)	NULL
.	NULL

We	NULL
gratefully	NULL
acknowledge	NULL
the	NULL
expert	NULL
secretarial	NULL
assistance	NULL
of	NULL
Debbie	NULL
Perrotte	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
for	NULL
the	NULL
expert	NULL
flow	NULL
cytometric	NULL
analyses	NULL
performed	NULL
by	NULL
Colette	NULL
Charland	NULL
and	NULL
Julie	NULL
Wolfe	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Azuara	NULL
,	NULL
V.	NULL
,	NULL
and	NULL
P.	NULL
Pereira	NULL
.	NULL

2000	NULL
.	NULL

Genetic	NULL
mapping	NULL
of	NULL
two	NULL
murine	NULL
loci	NULL
that	NULL
influence	NULL
the	NULL
development	NULL
of	NULL
IL-4-producing	NULL
Thy-1	NULL
dull	NULL
gamma	NULL
delta	NULL
thy-mocytes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

165:42-48	NULL
.	NULL

2	NULL
.	NULL

Born	NULL
,	NULL
W.	NULL
,	NULL
M.	NULL
Happ	NULL
,	NULL
A.	NULL
Dallas	NULL
,	NULL
C.	NULL
Reardon	NULL
,	NULL
R.	NULL
Kubo	NULL
,	NULL
T.	NULL
Shinnick	NULL
,	NULL
P.	NULL
Bren-nan	NULL
,	NULL
and	NULL
R.	NULL
O'Brien	NULL
.	NULL

1990	NULL
.	NULL

Recognition	NULL
of	NULL
heat	NULL
shock	NULL
proteins	NULL
and	NULL
gamma	NULL
delta	NULL
cell	NULL
function	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
1140-43	NULL
.	NULL

3	NULL
.	NULL

Cai	NULL
,	NULL
G.	NULL
,	NULL
T.	NULL
Radzanowski	NULL
,	NULL
E.	NULL
Villegas	NULL
,	NULL
R.	NULL
Kastelein	NULL
,	NULL
and	NULL
C.	NULL
Hunter	NULL
.	NULL

2000	NULL
.	NULL

Identification	NULL
of	NULL
STAT4-dependent	NULL
and	NULL
independent	NULL
mechanisms	NULL
of	NULL
resistance	NULL
to	NULL
Toxoplasma	NULL
gondii	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

165:2619-2627	NULL
.	NULL

4	NULL
.	NULL

Chomarat	NULL
,	NULL
P.	NULL
,	NULL
J.	NULL
Kjeldsen-Kragh	NULL
,	NULL
A.	NULL
Quayle	NULL
,	NULL
J.	NULL
Natvig	NULL
,	NULL
and	NULL
P.	NULL
Miossec	NULL
.	NULL

1994	NULL
.	NULL

Different	NULL
cytokine	NULL
production	NULL
profiles	NULL
of	NULL
gamma	NULL
delta	NULL
T	NULL
cell	NULL
clones	NULL
:	NULL
relation	NULL
to	NULL
inflammatory	NULL
arthritis	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24:2087-2091	NULL
.	NULL

5	NULL
.	NULL

Clark	NULL
,	NULL
D.	NULL
,	NULL
G.	NULL
Chaouat	NULL
,	NULL
P.	NULL
Arck	NULL
,	NULL
H.	NULL
Mittruccker	NULL
,	NULL
and	NULL
G.	NULL
Levy	NULL
.	NULL

1998	NULL
.	NULL

Cutting	NULL
edge	NULL
:	NULL
cytokine-dependent	NULL
abortion	NULL
in	NULL
CBA	NULL
x	NULL
DBA/2	NULL
mice	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
procoagulant	NULL
fg12	NULL
prothrombinase	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

160:545	NULL
.	NULL

6	NULL
.	NULL

D'Souza	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
Cooper	NULL
,	NULL
A.	NULL
Frank	NULL
,	NULL
R.	NULL
Mazzaccro	NULL
,	NULL
B.	NULL
Bloom	NULL
,	NULL
and	NULL
I.	NULL
Orme	NULL
.	NULL

1997	NULL
.	NULL

An	NULL
anti-inflammatory	NULL
role	NULL
for	NULL
gamma-delta	NULL
T	NULL
lymphocytes	NULL
in	NULL
acquired	NULL
immunity	NULL
to	NULL
mycobacterium	NULL
tuberculosis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:1217-1221	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

.	NULL

Ferrick	NULL
,	NULL
D.	NULL
,	NULL
M.	NULL
Schrenzel	NULL
,	NULL
T.	NULL
Mulvania	NULL
,	NULL
B.	NULL
Hsieh	NULL
,	NULL
W.	NULL
Ferlin	NULL
,	NULL
and	NULL
H.	NULL
Lepper	NULL
.	NULL

1995	NULL
.	NULL

Differential	NULL
production	NULL
of	NULL
interferon-gamma	NULL
and	NULL
interleukin-4	NULL
in	NULL
response	NULL
to	NULL
Th1-	NULL
and	NULL
Th2-stimulating	NULL
pathogens	NULL
by	NULL
gamma	NULL
delta	NULL
T	NULL
cells	NULL
in	NULL
vivo	NULL
.	NULL

Nature	NULL
373:255-257.	NULL
.	NULL

Fitch	NULL
,	NULL
F.	NULL
,	NULL
M.	NULL
McKisic	NULL
,	NULL
D.	NULL
Lancki	NULL
,	NULL
and	NULL
T.	NULL
Gajewski	NULL
.	NULL

1993	NULL
.	NULL

Differential	NULL
regu-	NULL
lation	NULL
of	NULL
T	NULL
lymphocyte	NULL
subsets	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

11:29-48.	NULL
.	NULL

Fu	NULL
,	NULL
Y.-X	NULL
.	NULL

,	NULL
C.	NULL
Roark	NULL
,	NULL
K.	NULL
Kelly	NULL
,	NULL
D.	NULL
Drevets	NULL
,	NULL
P.	NULL
Campbell	NULL
,	NULL
R.	NULL
O'Brien	NULL
,	NULL
and	NULL
W.	NULL
Born	NULL
.	NULL

1994	NULL
.	NULL

Immune	NULL
protection	NULL
and	NULL
control	NULL
of	NULL
inflammatory	NULL
tissue	NULL
necrosis	NULL
by	NULL
gamma-delta	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

153:3101	NULL
.	NULL

Gerber	NULL
,	NULL
D.	NULL
,	NULL
V.	NULL
Azuara	NULL
,	NULL
J.	NULL
Levraud	NULL
,	NULL
S.	NULL
Huang	NULL
,	NULL
M.	NULL
Lembezat	NULL
,	NULL
and	NULL
P.	NULL
Pereira	NULL
.	NULL

1999	NULL
.	NULL

IL-4-producing	NULL
gamma	NULL
delta	NULL
T	NULL
cells	NULL
that	NULL
express	NULL
a	NULL
very	NULL
restricted	NULL
TCR	NULL
repertoire	NULL
are	NULL
preferentially	NULL
localized	NULL
in	NULL
liver	NULL
and	NULL
spleen	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

163	NULL
:	NULL
3076-3082	NULL
.	NULL

Hoag	NULL
,	NULL
K.	NULL
,	NULL
M.	NULL
Lipscomb	NULL
,	NULL
and	NULL
A.	NULL
Izzo	NULL
.	NULL

1997	NULL
.	NULL

IL-12	NULL
and	NULL
IFN-y	NULL
are	NULL
required	NULL
for	NULL
initiating	NULL
the	NULL
protective	NULL
Th1	NULL
response	NULL
to	NULL
pulmonary	NULL
cryptococcosis	NULL
in	NULL
resistant	NULL
C.B-17	NULL
mice	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Respir	NULL
.	NULL

Cell	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

17:733-739	NULL
.	NULL

Hoshino	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Yagita	NULL
,	NULL
J.	NULL
Ortaldo	NULL
,	NULL
R.	NULL
Wiltrout	NULL
,	NULL
and	NULL
H.	NULL
Young	NULL
.	NULL

2000	NULL
.	NULL

In	NULL
vivo	NULL
administration	NULL
of	NULL
IL-18	NULL
can	NULL
induce	NULL
IgE	NULL
production	NULL
through	NULL
Th2	NULL
cytokine	NULL
induction	NULL
and	NULL
up-regulation	NULL
of	NULL
CD40	NULL
ligand	NULL
(	NULL
CD154	NULL
)	NULL
expression	NULL
on	NULL
CD4*	NULL
T	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

30:1998-2006	NULL
.	NULL

Hsieh	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Schrenzel	NULL
,	NULL
T.	NULL
Mulvania	NULL
,	NULL
H.	NULL
Lepper	NULL
,	NULL
L.	NULL
DiMolfetto-Landon	NULL
,	NULL
and	NULL
D.	NULL
Ferrick	NULL
.	NULL

1996	NULL
.	NULL

In	NULL
vitro	NULL
cytokine	NULL
production	NULL
in	NULL
murine	NULL
listeriosis	NULL
.	NULL

Evidence	NULL
for	NULL
immunoregulation	NULL
by	NULL
gamma	NULL
delta*	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

156:232-237	NULL
.	NULL

Huber	NULL
,	NULL
S.	NULL
,	NULL
D.	NULL
Graveline	NULL
,	NULL
M.	NULL
Newell	NULL
,	NULL
W.	NULL
Born	NULL
,	NULL
and	NULL
R.	NULL
O'Brien	NULL
.	NULL

2000	NULL
.	NULL

Vy1	NULL
*	NULL
T	NULL
cells	NULL
suppress	NULL
and	NULL
Vy4*	NULL
T	NULL
cells	NULL
promote	NULL
susceptibility	NULL
to	NULL
coxsackievirus	NULL
B3-induced	NULL
myocarditis	NULL
in	NULL
mice	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

165:4174-4181	NULL
.	NULL

Huber	NULL
,	NULL
S.	NULL
,	NULL
J.	NULL
Kupperman	NULL
,	NULL
and	NULL
M.	NULL
Newell	NULL
.	NULL

1999	NULL
.	NULL

Hormonal	NULL
regulation	NULL
of	NULL
CD4*	NULL
T-cell	NULL
responses	NULL
in	NULL
coxsackievirus	NULL
B3-induced	NULL
myocarditis	NULL
in	NULL
mice	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

73:4689-4695	NULL
.	NULL

Huber	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
P.	NULL
Lodge	NULL
.	NULL

1984	NULL
.	NULL

Coxsackievirus	NULL
B3	NULL
myocarditis	NULL
in	NULL
Balb/c	NULL
mice	NULL
:	NULL
evidence	NULL
for	NULL
autoimmunity	NULL
to	NULL
myocyte	NULL
antigens	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

116:21	NULL
.	NULL

Huber	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
Moraska	NULL
,	NULL
and	NULL
M.	NULL
Choate	NULL
.	NULL

1992	NULL
.	NULL

T	NULL
cells	NULL
expressing	NULL
the	NULL
y8	NULL
T-cell	NULL
receptor	NULL
potentiate	NULL
coxsackievirus	NULL
B3-induced	NULL
myocarditis	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:6541-6546	NULL
.	NULL

Huber	NULL
,	NULL
S.	NULL
,	NULL
A.	NULL
Mortensen	NULL
,	NULL
and	NULL
G.	NULL
Moulton	NULL
.	NULL

1996	NULL
.	NULL

Modulation	NULL
of	NULL
cytokine	NULL
expression	NULL
by	NULL
CD4*	NULL
T	NULL
cells	NULL
during	NULL
coxsackievirus	NULL
B3	NULL
infections	NULL
of	NULL
BALB/c	NULL
mice	NULL
initiated	NULL
by	NULL
cells	NULL
expressing	NULL
the	NULL
y8	NULL
*	NULL
T	NULL
cell	NULL
receptor	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:3039-3045	NULL
.	NULL

Huber	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
B.	NULL
Pfaeffle	NULL
.	NULL

1994	NULL
.	NULL

Differential	NULL
Thi	NULL
and	NULL
Th2	NULL
cell	NULL
responses	NULL
in	NULL
male	NULL
and	NULL
female	NULL
BALB/c	NULL
mice	NULL
infected	NULL
with	NULL
coxsackievirus	NULL
group	NULL
B	NULL
type	NULL
3	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

68:5126-5132	NULL
.	NULL

Jones-Carson	NULL
,	NULL
J.	NULL
,	NULL
A.	NULL
Vazquel-Torres	NULL
,	NULL
H.	NULL
van	NULL
der	NULL
Heyde	NULL
,	NULL
T.	NULL
Warner	NULL
,	NULL
R.	NULL
Wag-ner	NULL
,	NULL
and	NULL
E.	NULL
Balish	NULL
.	NULL

1995	NULL
.	NULL

Gamma-delta	NULL
T	NULL
cell-induced	NULL
nitric	NULL
oxide	NULL
production	NULL
enhances	NULL
resistance	NULL
to	NULL
mucosal	NULL
candidiasis	NULL
.	NULL

Nat	NULL
.	NULL

Med	NULL
.	NULL

1:552	NULL
.	NULL

Kishimoto	NULL
,	NULL
K.	NULL
,	NULL
V.	NULL
Dong	NULL
,	NULL
S.	NULL
Issazadeh	NULL
,	NULL
E.	NULL
Fedoseyeva	NULL
,	NULL
A.	NULL
Waaga	NULL
,	NULL
A.	NULL
Yamada	NULL
,	NULL
M.	NULL
Sho	NULL
,	NULL
G.	NULL
Benichou	NULL
,	NULL
H.	NULL
J.	NULL
Auchincloss	NULL
,	NULL
M.	NULL
Grusby	NULL
,	NULL
S.	NULL
Khoury	NULL
,	NULL
and	NULL
M.	NULL
Sayegh	NULL
.	NULL

2000	NULL
.	NULL

The	NULL
role	NULL
of	NULL
€CD154-CD40	NULL
versus	NULL
CD28-B7	NULL
costimulatory	NULL
pathways	NULL
in	NULL
regulating	NULL
allogeneic	NULL
Th1	NULL
and	NULL
Th2	NULL
responses	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Investig	NULL
.	NULL

106:63-72	NULL
.	NULL

Knowlton	NULL
,	NULL
K.	NULL
,	NULL
E.	NULL
Jeon	NULL
,	NULL
N.	NULL
Berkley	NULL
,	NULL
R.	NULL
Wessely	NULL
,	NULL
and	NULL
S.	NULL
Huber	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
mutation	NULL
in	NULL
the	NULL
puff	NULL
region	NULL
of	NULL
VP2	NULL
attenuates	NULL
the	NULL
myocarditic	NULL
phenotype	NULL
of	NULL
an	NULL
infectious	NULL
cDNA	NULL
of	NULL
the	NULL
Woodruff	NULL
variant	NULL
of	NULL
coxsackievirus	NULL
B3	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:7811-7818	NULL
.	NULL

Kodukula	NULL
,	NULL
P.	NULL
,	NULL
T.	NULL
Liu	NULL
,	NULL
N.	NULL
Rooijen	NULL
,	NULL
M.	NULL
Jager	NULL
,	NULL
and	NULL
R.	NULL
Hendricks	NULL
.	NULL

1999	NULL
.	NULL

Mac-rophage	NULL
control	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
type	NULL
1	NULL
replication	NULL
in	NULL
peripheral	NULL
nervous	NULL
system	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

162:2895-2905	NULL
.	NULL

Krenger	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
J.	NULL
Ferrara	NULL
.	NULL

1996	NULL
.	NULL

Graft-versus-host	NULL
disease	NULL
and	NULL
the	NULL
Th1/	NULL
Th2	NULL
paradigm	NULL
.	NULL

Immunol	NULL
.	NULL

Res	NULL
.	NULL

15:50-73	NULL
.	NULL

Lane	NULL
,	NULL
J.	NULL
,	NULL
D.	NULL
Neumann	NULL
,	NULL
A.	NULL
Lanfond-Walker	NULL
,	NULL
A.	NULL
Herskowitz	NULL
,	NULL
and	NULL
N.	NULL
Rose	NULL
.	NULL

1993	NULL
.	NULL

Role	NULL
of	NULL
IL-1	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
in	NULL
coxsackievirus-induced	NULL
autoimmune	NULL
myocarditis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:1682-1690	NULL
.	NULL

McMenamin	NULL
,	NULL
C.	NULL
,	NULL
C.	NULL
Pimm	NULL
,	NULL
M.	NULL
McKersey	NULL
,	NULL
and	NULL
P.	NULL
Holt	NULL
.	NULL

1994	NULL
.	NULL

Regulation	NULL
of	NULL
IgE	NULL
responses	NULL
to	NULL
inhaled	NULL
antigen	NULL
in	NULL
mice	NULL
by	NULL
antigen-specific	NULL
gamma-delta	NULL
*	NULL
T	NULL
cells	NULL
.	NULL

Science	NULL
265:1869-1873	NULL
.	NULL

Mombaerts	NULL
,	NULL
P.	NULL
,	NULL
J.	NULL
Arnoldi	NULL
,	NULL
F.	NULL
Russ	NULL
,	NULL
S.	NULL
Tonegawa	NULL
,	NULL
and	NULL
S.	NULL
Kaufmann	NULL
.	NULL

1993	NULL
.	NULL

Different	NULL
roles	NULL
of	NULL
alpha-beta	NULL
and	NULL
gamma-delta	NULL
T	NULL
cells	NULL
in	NULL
immunity	NULL
against	NULL
an	NULL
intracellular	NULL
bacterial	NULL
pathogen	NULL
.	NULL

Nature	NULL
365:53	NULL
.	NULL

Mukasa	NULL
,	NULL
A.	NULL
,	NULL
H.	NULL
Yoshida	NULL
,	NULL
N.	NULL
Kobayashi	NULL
,	NULL
G.	NULL
Matsuzaki	NULL
,	NULL
and	NULL
K.	NULL
Nomoto	NULL
.	NULL

1998	NULL
.	NULL

Gamma	NULL
delta	NULL
T	NULL
cells	NULL
in	NULL
infection-induced	NULL
and	NULL
autoimmune-induced	NULL
testic-ular	NULL
inflammation	NULL
.	NULL

Immunology	NULL
95:395-401	NULL
.	NULL

Murphy	NULL
,	NULL
K.	NULL
,	NULL
W.	NULL
Ouyang	NULL
,	NULL
J.	NULL
Farrar	NULL
,	NULL
J.	NULL
Yang	NULL
,	NULL
S.	NULL
Ranganath	NULL
,	NULL
H.	NULL
Asnagli	NULL
,	NULL
M.	NULL
Afkarian	NULL
,	NULL
and	NULL
T.	NULL
Murphy	NULL
.	NULL

2000	NULL
.	NULL

Signaling	NULL
and	NULL
transcription	NULL
in	NULL
T	NULL
helper	NULL
development	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

18:451-494	NULL
.	NULL

Naiki	NULL
,	NULL
Y.	NULL
,	NULL
H.	NULL
Nishimura	NULL
,	NULL
S.	NULL
Itohara	NULL
,	NULL
and	NULL
Y.	NULL
Yoshikai	NULL
.	NULL

2000	NULL
.	NULL

Gamma-delta	NULL
T	NULL
cells	NULL
may	NULL
dichotomously	NULL
modulate	NULL
infection	NULL
with	NULL
avirulent	NULL
Salmonella	NULL
chol-eracsuis	NULL
via	NULL
IFN-gamma	NULL
and	NULL
IL-13	NULL
in	NULL
mice	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

202:61-69	NULL
.	NULL

Nakamura	NULL
,	NULL
T.	NULL
,	NULL
G.	NULL
Matsuzaki	NULL
,	NULL
and	NULL
K.	NULL
Nomoto	NULL
.	NULL

1999	NULL
.	NULL

The	NULL
protective	NULL
role	NULL
of	NULL
T-cell	NULL
receptor	NULL
Vy1	NULL
``	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
primary	NULL
infection	NULL
with	NULL
Listeria	NULL
monocyto-genes	NULL
.	NULL

Immunology	NULL
96:29-34	NULL
.	NULL

Nicholson	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
V.	NULL
Kuchroo	NULL
.	NULL

1997	NULL
.	NULL

Manipulation	NULL
of	NULL
the	NULL
Th1/Th2	NULL
balance	NULL
in	NULL
autoimmune	NULL
disease	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

8:837-842	NULL
.	NULL

Ni	NULL
iya	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Takimoto	NULL
,	NULL
G.	NULL
M	NULL
ki	NULL
,	NULL
S.	NULL
H	NULL
H.	NULL
Yoshid	NULL
Y.	NULL
Yo	NULL
Vor	NULL
.	NULL

75	NULL
,	NULL
2001	NULL
34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38.	NULL
shikai	NULL
,	NULL
G.	NULL
Kimura	NULL
,	NULL
and	NULL
K.	NULL
Nomoto	NULL
.	NULL

2000	NULL
.	NULL

Vy1*	NULL
y8	NULL
T	NULL
cells	NULL
play	NULL
protective	NULL
roles	NULL
at	NULL
an	NULL
early	NULL
phase	NULL
of	NULL
murine	NULL
cytomegalovirus	NULL
infection	NULL
through	NULL
production	NULL
of	NULL
interferon	NULL
gamma	NULL
.	NULL

Immunology	NULL
99:187-194	NULL
.	NULL

O'Brien	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
X.	NULL
Yin	NULL
,	NULL
S.	NULL
A.	NULL
Huber	NULL
,	NULL
K.	NULL
Ikuta	NULL
,	NULL
and	NULL
W.	NULL
Born	NULL
.	NULL

2000	NULL
.	NULL

Depiction	NULL
of	NULL
a	NULL
gamma-delta	NULL
T	NULL
cell	NULL
subset	NULL
can	NULL
increase	NULL
host	NULL
resistance	NULL
to	NULL
a	NULL
bacterial	NULL
infection	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

165:6472-6479	NULL
.	NULL

Pelegri	NULL
,	NULL
C.	NULL
,	NULL
P.	NULL
Kublein	NULL
,	NULL
E.	NULL
Buchner	NULL
,	NULL
C.	NULL
B.	NULL
Schmidt	NULL
,	NULL
A.	NULL
Franch	NULL
,	NULL
M.	NULL
Castell	NULL
,	NULL
T.	NULL
Hunig	NULL
,	NULL
F.	NULL
Emmrich	NULL
,	NULL
and	NULL
R.	NULL
W.	NULL
Kinne	NULL
.	NULL

1996	NULL
.	NULL

Depiction	NULL
of	NULL
gamma	NULL
delta	NULL
T	NULL
cells	NULL
does	NULL
not	NULL
prevent	NULL
or	NULL
ameliorate	NULL
,	NULL
but	NULL
rather	NULL
aggravates	NULL
,	NULL
rat	NULL
adjuvant	NULL
arthritis	NULL
.	NULL

Arthritis	NULL
Rheum	NULL
.	NULL

38:204-215	NULL
.	NULL

Peterman	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
C.	NULL
Spencer	NULL
,	NULL
A.	NULL
I.	NULL
Sperling	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Bluestone	NULL
.	NULL

1993	NULL
.	NULL

Role	NULL
of	NULL
gamma	NULL
delta	NULL
T	NULL
cells	NULL
in	NULL
murine	NULL
collagen-induced	NULL
arthritis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:6546-6558	NULL
.	NULL

Romagnani	NULL
,	NULL
S.	NULL
1996	NULL
.	NULL

Thi	NULL
and	NULL
Th2	NULL
in	NULL
human	NULL
diseases	NULL
.	NULL

Clin	NULL
.	NULL

Immunol	NULL
.	NULL

Im-munopathol	NULL
.	NULL

80:225-235	NULL
.	NULL

Rossman	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
S.	NULL
Carding	NULL
.	NULL

1996	NULL
.	NULL

Gamma	NULL
delta	NULL
T	NULL
cells	NULL
in	NULL
asthma	NULL
.	NULL

Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

124:266-267	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44.	NULL
y8*	NULL
T	NULL
CELLS	NULL
IN	NULL
MYOCARDITIS	NULL
-	NULL
5869	NULL
.	NULL

Scharton	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
P.	NULL
Scott	NULL
.	NULL

1993	NULL
.	NULL

Natural	NULL
killer	NULL
cells	NULL
or	NULL
a	NULL
source	NULL
of	NULL
interferon	NULL
gamma	NULL
drives	NULL
differentiation	NULL
of	NULL
CD4~	NULL
T	NULL
cell	NULL
subsets	NULL
and	NULL
induces	NULL
carly	NULL
resistance	NULL
to	NULL
Leishmania	NULL
major	NULL
in	NULL
mice	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178:567	NULL
.	NULL

Tough	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
J.	NULL
Sprent	NULL
.	NULL

1998	NULL
.	NULL

Lifespan	NULL
of	NULL
gamma/delta	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187:357-365	NULL
.	NULL

Vincent	NULL
,	NULL
M.	NULL
,	NULL
K.	NULL
Roessner	NULL
,	NULL
D.	NULL
Lynch	NULL
,	NULL
D.	NULL
Wilson	NULL
,	NULL
S.	NULL
Cooper	NULL
,	NULL
J.	NULL
Tschopp	NULL
,	NULL
L.	NULL
Sigal	NULL
,	NULL
and	NULL
R.	NULL
Budd	NULL
.	NULL

1996	NULL
.	NULL

Apoptosis	NULL
of	NULL
Fashigh	NULL
CD4*	NULL
synovial	NULL
T	NULL
cells	NULL
by	NULL
borrelia-reactive	NULL
Fas-ligand	NULL
(	NULL
high	NULL
)	NULL
gamma	NULL
delta	NULL
T	NULL
cells	NULL
in	NULL
Lyme	NULL
arthritis	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184:2109-2117	NULL
.	NULL

Weintraub	NULL
,	NULL
B.	NULL
C.	NULL
,	NULL
M.	NULL
R.	NULL
Jackson	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Hedrick	NULL
.	NULL

1994	NULL
.	NULL

Gamma	NULL
delta	NULL
T	NULL
cells	NULL
can	NULL
recognize	NULL
nonclassical	NULL
MHC	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
conventional	NULL
anti-genic	NULL
peptides	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

153:3051-3058	NULL
.	NULL

Woodruff	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
J.	NULL
Woodruff	NULL
.	NULL

1974	NULL
.	NULL

Involvement	NULL
of	NULL
T	NULL
lymphocytes	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
coxsackievirus	NULL
B3	NULL
heart	NULL
disease	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

113:1726-1734	NULL
.	NULL

Zuany-Amorim	NULL
,	NULL
C.	NULL
,	NULL
C.	NULL
Ruffie	NULL
,	NULL
S.	NULL
Haile	NULL
,	NULL
B.	NULL
Vargaftig	NULL
,	NULL
P.	NULL
Pereira	NULL
,	NULL
and	NULL
M.	NULL
Pre-tolani	NULL
.	NULL

1998	NULL
.	NULL

Requirement	NULL
for	NULL
gamma	NULL
delta	NULL
T	NULL
cells	NULL
in	NULL
allergic	NULL
airway	NULL
inflammation	NULL
.	NULL

Science	NULL
280:1265-1267	NULL
.	NULL

